Gastroparesis

GASTROENTEROLOGY 2004;127:15921622
American Gastroenterological Association Technical Review on the Diagnosis and Treatment of Gastroparesis
This literature review and the recommendations herein were prepared for the American Gastroenterological Association Clinical Practice Committee. The paper was approved by the Committee on May 16, 2004, and by the AGA Governing Board on September 23, 2004.
ormal gastric emptying reects a coordinated effort between different regions of the stomach and the duodenum as well as extrinsic modulation by central nervous system (CNS) and distal gut factors. Important events related to normal gastric emptying include fundic relaxation to accommodate food, antral contractions for trituration of large food particles, pyloric relaxation to allow food to exit the stomach, and antropyloroduodenal coordination of motor events. Gastric dysmotility includes delayed gastric emptying (gastroparesis), rapid gastric emptying (as seen in dumping syndrome), and other motor dysfunctions such as impaired fundic distention most commonly found in functional dyspepsia. The importance of gastric dysrhythmias has not been clearly dened. Disorders of gastric motility may present with a spectrum of symptoms of variable severity. This technical review systematically assesses the clinical research literature and formulates recommendations for the diagnosis and management of patients with gastroparesis. The published peer-reviewed literature on gastroparesis was searched on PubMed using the key words gastroparesis, gastric motility, and gastric dysmotility. Referenced articles from published manuscripts, book chapters, and recent abstracts from national and international meetings were included in this review.
Symptoms and Clinical Presentation of Gastroparesis

Gastroparesis is a symptomatic chronic disorder of the stomach characterized by delayed gastric emptying in the absence of mechanical obstruction. Symptoms of gastroparesis are variable and include early satiety, nausea, vomiting, bloating, and upper abdominal discomfort. In 146 patients with gastroparesis, nausea was present in 92%, vomiting in 84%, abdominal bloating in 75%, and early satiety in 60%.1 Complications of gastroparesis may contribute to patient morbidity and include esophagitis, MalloryWeiss tear, and vegetableladen bezoars.2,3 Symptoms of gastroparesis are nonspecic and may mimic structural disorders such as ulcer disease, partial
gastric or small bowel obstruction, gastric cancer, and pancreaticobiliary disorders.2 There also is an overlap between the symptoms of gastroparesis and functional dyspepsia. Functional dyspepsia is characterized by chronic or recurrent upper abdominal discomfort; however, many individuals report symptoms of dysmotility, including nausea, vomiting, and early satiety, and subsets of patients with functional dyspepsia exhibit delays in gastric emptying.4,5 Indeed, idiopathic gastroparesis can be considered one of the causes of functional dyspepsia. Recently, a quantitative instrument for gastroparesisrelated symptoms has been validated.6 Symptom correlation with delayed gastric emptying is variable for diabetic gastropathy, idiopathic gastroparesis, and functional dyspepsia.79 In recent studies, early satiety, postprandial fullness, and vomiting have been reported to predict delayed emptying in patients with functional dyspepsia.4,5 In patients with diabetes, abdominal fullness and bloating were found to predict delayed gastric emptying.10 In some drug trials of prokinetic agents, the correlation between symptom improvement and acceleration of gastric emptying has been poor. In contrast, cisapride was reported to reduce epigastric pressure and bloating in association with improved emptying.11 In individuals with symptoms of gastroparesis who have normal rates of gastric emptying, other motor, myoelectric, or sensory abnormalities may elicit symptoms. Abdominal discomfort or pain is present in 46% 89% of patients with gastroparesis but is usually not the predominant symptom, in contrast to its prominence in functional dyspepsia.1,12 Abdominal pain in gastroparesis responds poorly to treatment of gastroparesis.12 Patients with functional dyspepsia exhibit heightened sensitivity to gastric distention suggestive of afferent neural dysAbbreviations used in this paper: CMV, cytomegalovirus; CNS, central nervous system; EGG, electrogastrography; FDA, Food and Drug Administration; GERD, gastroesophageal reux disease; MMC, migrating motor complex. 2004 by the American Gastroenterological Association 0016-5085/04/$30.00 doi:10.1053/j.gastro.2004.09.055
November 2004
AMERICAN GASTROENTEROLOGICAL ASSOCIATION
1593
function as a contributor to symptom pathogenesis.13 Similarly, in diabetic patients with dyspeptic symptoms, gastric distention elicits exaggerated nausea, bloating, and abdominal discomfort, suggesting that sensory nerve dysfunction may participate in symptom genesis in some patients with gastroparesis.14 The majority of patients with gastroparesis are women. In one large investigation, 82% of gastroparetic patients were female.1 Women tend to exhibit slower emptying rates than men, especially during the later portion of the menstrual cycle (the luteal phase).15,16 It is believed that gastric muscle contractility is reduced by progesterone. The prevalence and socioeconomic impact of gastroparesis are difcult to estimate due to the incomplete correlation of symptoms with gastric emptying and the apparently higher prevalence of the disorder in academic medical centers than in the community. Most population-based studies in patient subsets at risk for development of gastroparesis have focused on symptoms rather than gastric scintigraphy ndings. In such investigations, 11%18% of individuals with diabetes report symptoms consistent with upper gastrointestinal dysmotility such as nausea and vomiting.17,18 However, the prevalence of gastroparesis, as assessed by gastric emptying studies, in randomly selected patients in a diabetes clinic at an academic medical center was 48%.10 Using validated questionnaires, investigators have reported that symptoms of gastroparesis are associated with reduced quality of life both in diabetic patients and in community populations.19,20 Health care expenditures for care of gastroparesis are signicant. In an analysis of the 1998 North Carolina Hospital Discharge database, there were 45 admissions with a primary diagnosis of diabetic gastroparesis and an additional 1431 admissions for diabetic patients in which gastroparesis was a contributing factor to the need for hospitalization.21 The average hospital stay in this study was 5 days. In an unpublished study of patients with severe gastroparesis, health care costs from gastroparesis were estimated to average $6972 per patient per month.22 Most expenditures in this study were attributed to requirements for hospitalization and temporary or long-term use of intravenous hyperalimentation. Diagnostic testing in patients with presumed gastroparesis is associated with signicant costs, especially from performance of endoscopy and gastric emptying scintigraphy. For some less well-established diagnostic modalities performed in referral centers (eg, antroduodenal manometry, electrogastrography [EGG]), reimbursement from third-party payers may be difcult to obtain despite the recent granting of procedure codes.23 Similarly, novel
Table 1. Evaluation of Patients Suspected to Have Gastroparesis

1. Initial investigation A. History and physical examination B. Blood tests Complete blood count Complete metabolic prole, including glucose, potassium, creatinine, total protein, albumin, calcium Amylase, if abdominal pain is signicant symptom Pregnancy test, if appropriate C. Abdominal obstruction series, if vomiting or pain is acute or severe 2. Evaluate for organic disorders A. Upper endoscopy to evaluate for mechanical obstruction or mucosal lesions (alternative: barium upper gastrointestinal series, often with small bowel follow-through) B. Biliary ultrasonography if abdominal pain is a signicant symptom 3. Evaluate for delayed gastric emptying A. Solid-phase gastric emptying test B. Screen for secondary causes of gastroparesis Thyroid function tests (thyroid-stimulating hormone) Rheumatologic serologies (eg, antinuclear antibody, scleroderma antibody [Scl70]) Glycosylated hemoglobin (HbA1C) 4. Treatment trial with prokinetic agent and/or antiemetic agent 5. If no clinical response, consider further investigation A. EGG B. Antroduodenal manometry C. Small bowel evaluation with enteroclysis or small bowel followthrough D. Further laboratory tests, if indicated ANNA, tissue transglutaminase antibody
treatments for patients with refractory gastroparesis (eg, pyloric injection of botulinum toxin, gastric electrical stimulation) have been considered experimental by some insurers and reimbursement has been denied.
Evaluation of Patients With Suspected Gastroparesis

Overview of Diagnostic Approach Gastroparesis is diagnosed by demonstrating delayed gastric emptying in a symptomatic individual after exclusion of other potential etiologies of symptoms (Table 1). Gastroparesis is often suspected in patient subgroups with specic proles. Typical symptoms in an individual with long-standing type 1 diabetes mellitus suggest diabetic gastroparesis, whereas similar symptoms in a young woman are consistent with idiopathic gastroparesis. A diagnosis of functional dyspepsia may be entertained if pain is the dominant symptom, whereas coexistent defecation abnormalities suggest the possibility of irritable bowel syndrome. Delayed gastric emptying may develop after abdominal surgery, especially if the vagus nerve has been damaged. Vomiting associated with gastroparesis must be differentiated from regurgi-
1594
GASTROENTEROLOGY Vol. 127, No. 5
tation due to gastroesophageal reux disease (GERD) or rumination syndrome, episodic vomiting in cyclic vomiting syndrome, self-induced vomiting with bulimia, and abdominal pain and vomiting in superior mesenteric artery syndrome. Patients with long-standing, severe symptoms of gastroparesis may appear dehydrated or malnourished. A succussion splash, detected by auscultation over the epigastrium while moving the patient side to side or rapidly palpating the epigastrium, indicates excessive uid in the stomach from gastroparesis or mechanical gastric outlet obstruction.24 Most individuals suspected to have gastroparesis require upper endoscopy or a radiographic upper gastrointestinal series to exclude mechanical obstruction or ulcer disease. Mechanical gastric outlet obstruction can be caused by pyloric stenosis, neoplasia, or active ulcer disease in the duodenum, pyloric channel, or prepyloric antrum. The presence of retained food in the stomach after overnight fasting without obstruction is suggestive of gastroparesis. Bezoars may develop in severe cases. Endoscopy is more sensitive for detection of mucosal lesions than barium radiography.24 Double-contrast techniques have increased the sensitivity of radiologic studies. Contrast radiography of the small intestine is performed in those patients with refractory symptoms, those with symptoms suggestive of a small bowel etiology (eg, profound distention, steatorrhea, feculent emesis), or those who exhibit dilated small bowel loops on plain radiography. When upper gastrointestinal radiography is ordered, a small bowel follow-through can be included to screen for small bowel lesions. The small bowel follow-through is accurate for detection of highgrade small bowel obstruction, usually provides an adequate assessment of the terminal ileum, and may rarely suggest superior mesenteric artery syndrome. Enteroclysis (small bowel enema), obtained after placement of a nasoduodenal or oroduodenal tube, provides double-contrast images and is more accurate in detecting small intestinal mucosal lesions, mild to intermediate grades of obstruction, and small bowel neoplasia.25 Computed tomographic scanning with oral and intravenous contrast may also be useful for detection and localization of intestinal obstruction. After exclusion of mechanical disease of the stomach and small bowel, determination of the rate of gastric emptying of solid foods is usually obtained using scintigraphy. An abnormal gastric emptying test result suggests but does not prove that symptoms are caused by gastroparesis. If gastric emptying is normal, other causes for symptoms should be considered. However, a disorder of gastric motor function cannot be dismissed in symptomatic patients with normal gastric emptying because
regional dysfunctions of the stomach, including impaired fundic relaxation or gastric myoelectric dysrhythmias, may be associated with symptoms.26 Other testing to complement the nding of delayed gastric emptying includes thyroid chemistries to rule out hypothyroidism, glycosylated hemoglobin levels to assess long-term glycemic control in diabetic patients, and other blood tests to screen for rheumatologic disorders, neuromuscular conditions, or paraneoplastic phenomena. Idiopathic gastroparesis is diagnosed after other causes are excluded. Evaluation of Gastric Emptying, Motor Function, and Myoelectric Activity Several methods have been proposed for quantication of gastric emptying, motor function, and myoelectric activity (Table 2). Radiographic contrast techniques. The upper gastrointestinal barium series is an insensitive method for measuring gastric emptying because it is difcult to quantitate the relative fraction of contrast delivered to the intestine and because barium is not a physiologic test meal.27 Nevertheless, gastric retention may be suggested by poor emptying of barium from the stomach, gastric dilation, and the presence of retained food or a gastric bezoar. Little or no emptying of barium at 30 minutes and retention of gastric barium at 6 hours are suggestive of gastroparesis.28 The greatest value of barium radiography lies in the exclusion of mucosal lesions and mechanical outlet obstruction. Gastric emptying scintigraphy. Gastric emptying scintigraphy of a solid-phase meal is considered the gold standard for the diagnosis of gastroparesis because this test quanties the emptying of a physiologic caloric meal. Measurement of gastric emptying of solids is more sensitive for detection of gastroparesis because liquid emptying may remain normal even in patients with advanced disease. Liquid-phase emptying scans are more commonly performed after gastric surgery in patients suspected of having dumping syndrome. The usefulness of gastric scintigraphy in directing therapy and predicting response has been debated.11,29 Some clinicians have proposed performance of dual solid- and liquid-emptying scintigraphy in patients who have undergone gastric surgery to determine if symptoms might result from delayed solid emptying or rapid liquid emptying. For solid-phase testing, most centers use a 99mTc sulfur colloidlabeled egg sandwich as a test meal.27 More recently, a meal using Eggbeaters egg whites (ConAgra Foods, Inc, Downers, IL) with standard imaging at 0, 1, 2, and 4 hours postprandially has been proposed to provide a degree of standardization between different
November 2004
1595
Table 2. Tests to Assess Gastric Motor and Myoelectrical Function

Advantages Tests assessing gastric emptying Upper gastrointestinal barium radiographic study Scintigraphy Assess for mucosal lesions Gold standard Noninvasive Able to assess solid and liquid emptying Noninvasive Noninvasive Physiologic Noninvasive Disadvantages Nonphysiologic Radiation exposure (moderate) Radiation exposure (minimal)
Breath tests using
13
Ultrasonography for serial changes in antral area Magnetic resonance imaging Tests assessing gastric contractile activity Antroduodenal manometry Gastric barostat Tests assessing gastric myoelectrical activity EGG Tests assessing gastric accommodation Gastric barostat
Need normal small intestinal absorption, liver metabolism, pulmonary excretion Requires expertise for imaging and interpretation Primarily measures liquid emptying Expensive, time consuming Need specialized centers and software Invasive Need expertise to perform and interpret Invasive Research technique Movement artifact may make recording difcult to interpret Invasive Research technique Balloon may interfere with accommodation Simple Not well standardized or accepted
Assesses contractility in fasting and postprandial periods Measures proximal stomach relaxation and contraction Noninvasive
Measures proximal stomach accommodation response Measures combination of accommodation and sensitivity
Satiety test
Adapted from Quigley et al24 and Hasler WL, Koch KL. Diabetic gastroparesis. AGA Postgraduate Course, May 19 20, 2001.
centers.30 This test meal has a very low fat content and theoretically might produce different results than conventional meals. Whatever meal is used, the radiolabel needs to be cooked into it to ensure radioisotope binding to the solid phase. This prevents elution of the radiotracer into the liquid phase, which might produce an erroneous measurement of the faster liquid-phase gastric emptying.31 Scintigraphic assessment of emptying should be extended to at least 2 hours after meal ingestion. Even with extension of the scintigraphic study to this length, there may be signicant day-to-day variability (up to 20%) in rates of gastric emptying.32 For shorter durations, the test is less reliable due to larger variations of normal gastric emptying. Extending scintigraphy to 4 hours has been advocated by some investigators to improve the accuracy in determining the presence of gastroparesis.33,34 Emptying of solids typically exhibits a lag phase followed by a prolonged linear emptying phase. A variety of parameters can be calculated from the emptying prole of a radiolabeled meal. The simplest approach for interpreting a gastric emptying study is to report the percent retention at dened times after meal ingestion (usually 2 and 4 hours). The half emptying time also may be calculated; however, extrapolation of the emptying curve from an individual who did not empty 50% of the
ingested meal during the actual imaging time may provide an inaccurate determination of the half emptying time.35 Patients should discontinue medications that may affect gastric emptying for an adequate period before this test based on drug half-life (Table 3). For most medications, this will be 48 72 hours. Opiate analgesics and anticholinergic agents delay gastric emptying. Prokinetic agents that accelerate emptying may give a falsely normal gastric emptying result. Serotonin receptor antagonists such as ondansetron, which have little effect on gastric emptying, may be given for severe symptoms before performance of gastric scintigraphy. Hyperglycemia (glucose level 270 mg/dL) delays gastric emptying in diabetic patients.26 It is not unreasonable to defer gastric emptying testing until relative euglycemia is achieved to obtain a reliable determination of emptying parameters in the absence of acute metabolic derangement. Premenopausal women have slower gastric emptying than men,15,16 so some advocate using separate reference values for premenopausal women.4 Breath testing for gastroparesis. Breath tests using the nonradioactive isotope 13C bound to a digestible substance have been validated for measuring gastric emptying. Most commonly, 13C-labeled octanoate, a mediumchain triglyceride, is bound into a solid meal such as a
1596
Table 3. Medications That Affect Gastric Emptying

Delay gastric emptying Opioid analgesics Anticholinergic agents Tricyclic antidepressants Calcium channel blockers Progesterone Octreotide Proton pump inhibitors H2-receptor antagonists Interferon alfa L-dopa Fiber Sucralfate Aluminum hydroxide antacids -adrenergic receptor agonists Glucagon Calcitonin Dexfenuramine Diphenhydramine Alcohol Tobacco/nicotine Tetrahydrocannabinol Accelerate gastric emptying Prokinetic agents Metoclopramide Erythromycin/clarithromycin Cisapride Domperidone Tegaserod -adrenergic receptor antagonists
mufn.36 38 Other studies have bound 13C to acetate or to proteinaceous algae (Spirulina).31 After ingestion and stomach emptying, 13C-octanoate is absorbed in the small intestine and metabolized to 13CO2, which is then expelled from the lungs during respiration. The ratelimiting step is the rate of solid gastric emptying. Thus, octanoate breath testing provides a measure of solidphase emptying. The octanoate breath test provides reproducible results that correlate with ndings on gastric emptying scintigraphy.36 38 13C breath tests do not use ionizing radiation and can be used to test patients in the community or even at the bedside, where gamma camera facilities are not readily available. Breath samples can be preserved and shipped to a laboratory for analysis. Most octanoate breath testing is performed for clinical research and pharmaceutical studies. The penetrance of this diagnostic modality into clinical practice has been limited. Validation of this test in patients with emphysema, cirrhosis, celiac sprue, and pancreatic insufciency is needed, because rates of octanoate metabolism may be impaired in these disorders. EGG. EGG records gastric myoelectrical activity, known as the slow wave, using cutaneous electrodes afxed to the anterior abdomen overlying the stomach.39 The slow wave is responsible for controlling the maximal
frequency and the controlled aboral propagation of distal gastric contractions. The normal gastric slow wave frequency is approximately 3 cpm. Meal ingestion increases the amplitude of the EGG signal, which is believed to result either from increased antral contractility or from mechanical distention of the stomach. EGG testing quanties the dominant frequency and regularity of gastric myoelectrical activity, quanties the percentage of time in which abnormal slow wave rhythms are present during fasting and postprandially, and assesses the increase in amplitude (or power) after a meal.35 In general, an abnormal EGG is dened when the percent time in dysrhythmias exceeds 30% of the recording time and/or when meal ingestion fails to elicit an increase in signal amplitude.40 Gastric dysrhythmias (tachygastria, bradygastria) and decreased EGG amplitude responses to meal ingestion have been characterized in patients with idiopathic and diabetic gastroparesis.41 Gastric myoelectric abnormalities also have been described in patients with unexplained nausea and vomiting, motion sickness, and nausea and vomiting of pregnancy.35 EGG abnormalities are present in 75% of patients with gastroparesis versus 25% of symptomatic patients with normal gastric emptying.40 Some investigators suggest that EGG abnormalities and delayed gastric emptying may dene slightly different patient populations with dyspeptic symptoms.42 Symptomatic responses to antiemetic or prokinetic drug treatments have correlated better with resolution of gastric dysrhythmias than acceleration of delayed emptying in some patient subsets.8 Hyperglycemia may provoke dysrhythmias in diabetic patients.43 Clinically, EGG has been used to demonstrate gastric myoelectric abnormalities in patients with unexplained nausea and vomiting or functional dyspepsia. EGG is considered an adjunct to gastric emptying scintigraphy as part of a comprehensive evaluation of patients with refractory symptoms suggestive of an upper gastrointestinal motility disorder.35,40 However, to date, there has been little investigation to validate the utility of EGG in the management of patients with suspected gastric dysmotility. Antroduodenal manometry. Antroduodenal manometry provides information about gastric and duodenal motor function in both fasting and postprandial periods.35,44 Manometry may be performed in stationary settings over a 5- to 8-hour period or in ambulatory fashion over 24 hours using solid-state transducers. Ambulatory studies afford the advantage of correlating symptoms with abnormal motor patterns; however, catheter migration in these studies may limit interpretation of gastric motility. Rather, ambulatory manometry is
November 2004
1597
best reserved for characterization of duodenal motor function. The proposed indications for antroduodenal manometry include (1) characterization of motor dysfunction in patients with unexplained nausea and vomiting, (2) delineation of the cause of gastric or small bowel stasis (eg, visceral neuropathy or myopathy), and (3) support of a suspected diagnosis of chronic intestinal pseudo-obstruction.35 Distinct gastrointestinal motor patterns are present in the interdigestive (fasting) and digestive (fed) periods. The interdigestive (fasting) pattern consists of 3 cyclical phases known as the migrating motor complex (MMC) that recur at approximately 2-hour intervals unless interrupted by a meal. Phase I is a period of motor quiescence that is followed by a period of intermittent phasic contractions (phase II). The MMC culminates in a burst of regular rhythmic contractions that propagate from the antrum through the proximal small intestine (phase III, activity front). The intense propulsive contractions during phase III have been considered to be a physiologic intestinal housekeeper and are responsible for clearance of dietary ber and indigestible solids from the upper gut. Feeding disrupts the MMC and replaces it with a fed motor pattern of more regular antral and duodenal contractions of variable amplitude that may be either segmental or propagative in character. In gastroparesis, antroduodenal manometry may exhibit a decreased frequency/force of antral contractions and origination of most phase III complexes in the duodenum. In some individuals, increased tonic and phasic activity of the pylorus (pylorospasm) or irregular bursts of small intestinal contractions may be observed.45 Furthermore, the prevalence of concomitant small intestinal motor dysfunction in patients with gastroparesis ranges from 17% to 85% in different studies.46,47 Antroduodenal manometry can help conrm or exclude an underlying dysmotility syndrome when results of gastric emptying testing are normal or borderline. With an accurate stationary recording, reductions in the postprandial distal antral motility index correlate with impaired gastric emptying of solids.48 Normal ndings on manometry coupled with a normal transit test result strongly suggest that antral motor dysfunction is not the cause of symptoms.35 Antroduodenal manometry may differentiate between small intestinal neuropathic and myopathic disease and may suggest unsuspected small bowel obstruction or a rumination syndrome.35,49 Myopathic disorders, such as scleroderma or amyloidosis, produce contractile activity of abnormally low amplitude, whereas neuropathic conditions are characterized by contractions of normal amplitude with abnormal propagation, including loss of
intestinal phase III, random bursts, and failure of conversion to the fed pattern after meal ingestion. Occult mechanical obstruction of the small intestine may be suggested by 2 patterns of small bowel motor abnormalities: (1) postprandial clustered contractions for 30 minutes duration separated by quiescence or (2) simultaneous prolonged ( 8 seconds) or summated contractions suggesting a common cavity phenomenon from a dilated segment of intestine.50 In some patients with rumination syndrome, antroduodenal manometry may demonstrate a characteristic pattern of simultaneous contractions in all recording sites (R waves) secondary to increases in intra-abdominal pressures from somatic muscle activity, especially during the postprandial period.51 In pediatric studies, the absence of MMCs predicts a poor response to prokinetic agents.52 Some investigators perform antroduodenal manometry with infusions of erythromycin and/or octreotide to predict the patients clinical response to long-term treatment with these agents.53 Other studies have suggested that ndings of antroduodenal manometry may inuence treatment decisions in small numbers of patients ( 20%) with dysmotility syndromes.54 Validation of manometry as a critical diagnostic test for managing patients with suspected gastric or small intestinal dysmotility is incomplete. Other tests of gastric motor function. Several other techniques for measuring gastric motor function have been proposed. Ultrasonography. Transabdominal ultrasonography measures several parameters of gastric motor function. Serial changes in antral cross-sectional area can provide an index of gastric emptying.55 Gastric emptying is considered complete when the antral area returns to the fasting baseline level. Duplex sonography can quantify transpyloric ow of liquid gastric contents. Ultrasonography also has been used to measure accommodation in the proximal stomach.31 Unfortunately, ultrasound determinations of gastric emptying are operator dependent and have proven reliable only for measurements of liquid emptying rates. Testing may be difcult in obese individuals. As a consequence of these drawbacks, ultrasonography most commonly is used only in research settings. Magnetic resonance imaging. Magnetic resonance imaging can measure gastric emptying and accommodation using transaxial abdominal scans every 15 minutes.31 Magnetic resonance imaging can differentiate between gastric meal volume and total gastric volume, allowing determination of gastric secretory rates. This noninvasive, radiation-free test is appealing; however, the specialized equipment, time needed for interpreta-
1598
tion, and expense have limited its use to clinical research primarily in European centers. Single-photon emission computed tomography. Radionuclide imaging of the gastric wall following the intravenous injection of 99mTc pertechnetate, which localizes in the gastric mucosa, with subsequent single-photon emission computed tomography imaging has been used as a noninvasive measure of gastric accommodation.56 In 32 patients with functional dyspepsia, single-photon emission computed tomography imaging after 99mTc pertechnetate infusion suggested that impaired gastric accommodation (41%) may be detected more commonly than delayed emptying (9%) in dyspeptic patients referred to tertiary centers.57 The majority of dyspeptic patients had normal emptying and accommodation. Satiety testing. Satiety testing with symptom-limited consumption of a test liquid has been proposed as a noninvasive technique to evaluate accommodation. In the water load test, the patient drinks water until he or she feels very full.58 Other investigators have used nutrient-containing test meals that are consumed at a xed slow rate until satiety is achieved.59,60 Results of satiety testing correlate with the degree of gastric accommodation as measured by a barostat. Satiety tests offer the potential to noninvasively evaluate for abnormalities of gastric accommodation and perhaps visceral sensitivity.31 To date, most studies have quantied defects in satiety in patients with functional dyspepsia. Investigations characterizing responses to satiety testing have not been reported in patients with gastroparesis.
Table 4. Etiology of Gastroparesis (Nonobstructive Delayed Gastric Emptying)

Idiopathic Diabetes mellitus Postsurgical Partial gastric resection/vagotomy Postbariatric surgery Nissen fundoplication Transplantation: lung, heart-lung Gastrointestinal disorders associated with delayed gastric emptying Diffuse gastrointestinal motor disorders (eg, chronic intestinal pseudo-obstruction) GERD Achalasia Gastric ulcer Atrophic gastritis Functional dyspepsia Hypertrophic pyloric stenosis Celiac disease Nongastrointestinal disorders associated with delayed gastric emptying Eating disorders: anorexia Neurologic disorders CNS tumors Parkinsons disease Collagen vascular disorders Scleroderma Systemic lupus erythematosus Amyloidosis Endocrine and metabolic disorders Thyroid dysfunction Parathyroid dysfunction Chronic renal insufciency Gastric infection Chronic mesenteric ischemia Tumor associated (paraneoplastic) Medication associated
Disorders With Delayed Gastric Emptying (Gastroparesis)

Gastroparesis occurs in many clinical settings; idiopathic, diabetic, and postsurgical etiologies comprise the majority of cases in most series. In one series of 146 patients, gastroparesis was idiopathic in 36%, diabetic in 29%, and postsurgical in 13% of patients.1 Several gastrointestinal and systemic diseases are associated with gastroparesis (Table 4). Selected individual disorders frequently referred to gastroenterologists for evaluation and management are discussed in the following text. Diabetic Gastroparesis Gastroparesis is a recognized complication of diabetes mellitus and is classically considered to occur in those individuals with long-standing type 1 diabetes mellitus and other associated complications such as retinopathy, nephropathy, and peripheral neuropathy. Many affected patients have associated ndings of dysautonomia, including postural hypotension. Longitudi-
nal studies suggest that delayed gastric emptying is present in 25%55% of patients with type 1 diabetes mellitus and is not correlated with nongastrointestinal complications.61,62 Gastroparesis has also been described in approximately 30% of patients with type 2 diabetes mellitus.7 However, highly variable rates of gastric emptying, including acceleration of transit, have been reported in type 1 diabetes mellitus and type 2 diabetes mellitus, suggesting that development of gastroparesis is not universal or inevitable.62,63 Many individuals with rapid emptying have diabetes of relatively short duration. In those with accelerated emptying, impairment of fundic receptive relaxation to meal ingestion may be pathogenic of the motor defect.64 Gastroparesis traditionally has been considered to confer a poor prognosis for affected diabetic patients; however, recent investigations suggest that this may be incorrect.61 Clinical consequences of diabetic gastroparesis include induction of gastrointestinal symptoms, alteration in drug absorption, and destabilization of glycemic control.61 Symptoms in affected diabetic patients include
November 2004
1599
nausea, vomiting, early satiety, fullness, and abdominal discomfort. The presence of abdominal bloating and fullness particularly seems to be associated with the magnitude of emptying delay.10 Symptom severity, however, does not necessarily correlate well with the degree of gastric stasis.7,65 Some patients with severe symptoms may have near-normal to normal emptying patterns. In these individuals, other abnormalities, including impaired fundic relaxation, gastric slow wave dysrhythmias, or visceral hypersensitivity, may be potentially responsible for dyspeptic symptoms.7 The term diabetic gastropathy is commonly used because symptoms may not predict delays in gastric emptying and responses to prokinetic treatment may not be consequences of accelerated emptying. Changes in gastric emptying may affect postprandial blood glucose concentrations. Delayed gastric emptying contributes to poor glycemic control because of unpredictable delivery of food into the duodenum.66 Impaired gastric emptying with continued administration of exogenous insulin may produce hypoglycemia. Conversely, acceleration of emptying has been reported to cause hyperglycemia.63 Problems with blood glucose control may be the rst indication that a diabetic patient is developing gastroparesis.66 In type 1 diabetic patients with gastroparesis, prokinetic therapy may potentially benet glycemic control although this has not been universally observed.67 69 Long-term oral administration of the prokinetic agents levosulpiride and erythromycin have decreased plasma glucose and glycosylated hemoglobin levels in diabetic patients.70,71 However, studies with cisapride suggested that long-term improvement in gastric emptying had no effect on overall glycemic control in patients with type 1 diabetes mellitus.72,73 Diabetic gastroparesis is likely to result from impaired neural control of gastric motility, possibly at the level of the vagus nerve. In one investigation, morphologic abnormalities of the gastric myenteric plexus or vagus in diabetic patients were not identied by conventional histology,74 although abnormal myenteric neurotransmission involving both inhibitory and excitatory pathways has been described in animal models of diabetes. Conversely, in an older autopsy study of diabetic patients, inammatory changes were observed in some autonomic ganglia and dropout of vagal myelinated bers was noted.75 Other factors, including impairment of the inhibitory nitric oxide containing nerves,76 damage of the pacemaker interstitial cells of Cajal,77 and underlying smooth muscle dysfunction, have been described in animal models and patients with diabetic gastroparesis.78 80 In one study, selective loss of pyloric NO synthase was shown to contribute to gastroparesis in an
animal model and was reversible by administration of insulin or agents that restore NO activity.81 Hyperglycemia alone also may reversibly affect gastric motility and reduce the effectiveness of prokinetic agents. Hyperglycemia decreases antral contractility, decreases antral phase III of the MMC, increases pyloric contractions, causes gastric dysrhythmias (primarily tachygastria), delays gastric emptying, and even modulates fundic relaxation properties.43,66 Normalization of serum glucose levels in hyperglycemic patients has been shown to stabilize gastric myoelectric activity, improve gastric emptying, and restore antral phase III activity.82 Hyperglycemia appears to cause a reversible impairment of vagal efferent function.83 Glucose-responsive neurons have been identied in the CNS that may modify vagal efferent activity.84 Prostaglandins may also be involved, because indomethacin can reverse abnormal gastric electrical rhythms that occur during hyperglycemia in healthy volunteers.85 Patients with type 1 diabetes mellitus also exhibit increased perception of gastric distention, with exaggerated nausea, fullness, and epigastric pain for a given distending stimulus.14 In addition to its effects on motor function, hyperglycemia increases nausea and fullness during proximal gastric distention.66,86 Increased sensitivity of the proximal stomach may be responsible for postprandial dyspeptic symptoms when the stomach is distended by a meal.14,86 Postsurgical Gastroparesis Gastroparesis may occur as a complication of a number of different surgical procedures. Historically, most cases have resulted from performance of vagotomy in concert with gastric drainage for medically refractory peptic ulcer disease. More recently, with the advent of laparoscopic techniques to treat GERD, more individuals are presenting with gastroparesis as a complication of fundoplication. Postvagotomy gastroparesis. Postsurgical gastroparesis is most often a consequence of peptic ulcer surgery, usually with concurrent performance of vagotomy.87 The vagus nerves regulate both meal-evoked fundic relaxations and phasic antral contractions. The effects of complete vagal denervation are to accelerate gastric emptying of liquids and to retard emptying of solids. To avert the gastroparetic effects of vagotomy, most surgeons perform a gastric drainage procedure such as a pyloroplasty or gastroenterostomy. In most patients, the net result is that vagotomy combined with a drainage procedure produces little alteration in gastric emptying. Approximately 5% of patients undergoing vagotomy with antral resection and gastrojejunostomy develop se-
1600
vere postsurgical gastroparesis.87 In these individuals, the antrum is not present to triturate solids and the proximal stomach is unable to generate sufcient pressure to empty solid food residue. The Roux-en-Y stasis syndrome is characterized by postprandial abdominal pain, bloating, nausea, and vomiting.87 The combination of vagotomy, distal gastric resection, and Roux-en-Y gastrojejunostomy predisposes to severe gastric stasis as a result of both slow emptying from the gastric remnant and delayed small bowel transit in the denervated Roux efferent limb.87 Ectopic jejunal pacemakers may develop in the transected and reattached jejunal segment. Furthermore, myoelectric and motor activity in the Roux limb may be retrograde, causing reverse peristalsis toward the stomach and allowing the Roux limb to cause a functional obstruction.88
Postfundoplication gastric motor dysfunction.
proximal pouch. With gastric bypass, induction of early satiety by the small gastric pouch precludes ingestion of large meals. Solid gastric emptying is slower and liquid emptying is more rapid after gastric bypass surgery.98 The gastrojejunostomy conguration also can produce a relative malabsorptive state and promotes dumping syndrome if a high-carbohydrate liquid meal is ingested. Less commonly performed surgeries are gastric restrictive procedures such as vertical-banded gastroplasty and adjustable gastric banding. Vomiting has been reported to occur in 21% of patients after vertical-banded gastroplasty.99 Another study observed normal emptying from the proximal pouch.100
Gastroparesis after lung and heart-lung transplantation. Gastroparesis has been reported after heart
Mild acceleration of gastric emptying has been reported to occur after Nissen fundoplication and has been attributed to increased intragastric pressure due to prevention of fundic receptive relaxation from the mechanical effects of the wrap.89,90 This is supported by regional scintigraphic studies showing rapid proximal gastric emptying after fundoplication. These effects of fundoplication may promote development of early satiety.90 In some patients with reux who have preexisting delayed gastric emptying, fundoplication may normalize emptying.90 In other patients, early satiety, postprandial fullness, nausea, and vomiting develop after fundoplication as a consequence of postprandial antral hypomotility or delayed gastric emptying.9193 The delay in emptying may have preceded the surgery but was unrecognized at the time of operation. The development of postoperative gastroparesis after an open Nissen fundoplication is uncommon but at times may result in signicant morbidity.93 Vagal nerve injury occurs in 4% 40% of patients undergoing laparoscopic fundoplication.94,95 The gasbloat syndrome refers to postoperative gaseous symptoms, including inability to belch, pain, and bloating. Gas bloat postoperatively occurs more often in patients with preoperative delayed gastric emptying.96 Thus, preexistent gastroparesis has been considered a relative contraindication to performance of fundoplication for GERD. Postbariatric surgery. Surgical therapy for morbid obesity has become popular over the past 5 years. Most operations are designed to restrict the size of the stomach.97 The most commonly performed surgical procedure is the Roux-en-Y gastric bypass, in which the stomach is partitioned into a small proximal fundic pouch and a bypassed distal stomach. A loop gastrojejunostomy through a small gastroenterostomy drains the
and lung transplantation.101103 This may have serious consequences in the patient receiving a lung transplant, because gastroparesis predisposes to development of gastroesophageal reux with microaspiration and subsequent pulmonary infection. Symptomatic delays in gastric emptying have been reported in 25% of patients after single lung transplantation and 50% of patients after combined heart-lung transplantation.101 Another study reported delayed gastric emptying in 8 of 10 patients after combined heart-lung transplantation.102 Explanations include vagal nerve dysfunction or injury during surgery, opportunistic viral infection secondary to immunosuppressive medications, and motor-inhibitory effects of the immunosuppressive drugs themselves. Vagal nerve dysfunction from thermal or ischemic injury and/or dissection of the posterior mediastinum during surgery has been suggested as the most likely culprit.101103 Idiopathic Gastroparesis Idiopathic gastroparesis refers to symptomatic disease in patients with no primary underlying abnormality. This may represent the most common form of gastroparesis.1 As with other causes of gastroparesis, symptoms may uctuate, with episodes of pronounced symptoms interspersed with relatively symptom-free intervals. Most patients with idiopathic gastroparesis are women; typically the condition presents in young or middle-aged individuals.4 Symptoms of idiopathic gastroparesis overlap with those of functional dyspepsia; in some individuals, it may be difcult to provide a denitive distinction between the two. Abdominal pain/discomfort typically is the predominant symptom in functional dyspepsia, whereas nausea, vomiting, early satiety, and bloating predominate in idiopathic gastroparesis. The histologic basis of idiopathic gastroparesis is poorly understood. In one case, myenteric hypogangli-
November 2004
1601
onosis and reductions in numbers of interstitial cells of Cajal were observed.104 A subset of patients with idiopathic gastroparesis report sudden onset of symptoms after a viral prodrome, suggesting a potential viral etiology for their symptoms. In one series, a postviral etiology was suspected in 23% of cases based on histories of viral prodromes rather than any microbiologic conrmation.105 In this patient subset, previously healthy subjects develop the sudden onset of nausea, vomiting, diarrhea, fever, and cramps suggestive of a systemic viremic response. However, instead of experiencing resolution of symptoms, these individuals note persistent nausea, vomiting, and early satiety for more than 3 months and exhibit delays in gastric emptying on scintigraphy. Viruses that have been implicated in rare cases include cytomegalovirus, EpsteinBarr virus, and varicella zoster. However, the responsible organism remains elusive in most patients with postviral gastroparesis. These patients appear to have slow resolution of their symptoms over several years.105,106 In contrast, individuals with idiopathic gastroparesis without a viral trigger tend to show less improvement over time.105 Other Disorders Associated With Delayed Gastric Emptying Other gastrointestinal and nongastrointestinal disorders can be associated with gastroparesis. Some conditions produce similar symptoms but do not always delay emptying.
Gastrointestinal disorders with associated delayed gastric emptying. Gastroparesis associated with
GERD. Delayed gastric emptying has been detected in subsets of patients with GERD. Some investigators have reported gastroparesis prevalence rates of 40% in patients with GERD,107 whereas others have observed a much lower prevalence (10%).108 The role of delayed gastric emptying in the pathophysiology of GERD remains controversial. Gastric stasis with distention may promote transient lower esophageal sphincter relaxations with subsequent gastroesophageal reux of acid.109 Recent studies suggest that slow emptying from the proximal stomach, but not from the overall stomach, may correlate with esophageal acid exposure.110 Even though a causative role is unproved, it is not unreasonable to perform gastric scintigraphy in patients with GERD symptoms refractory to acid-suppressive therapy. Such testing also should be considered in those individuals considered for procedures to increase the barrier function of the gastroesophageal junction, including fundoplication to reduce the likelihood of postoperative complications as described previously.96
Hypertrophic pyloric stenosis. Infantile hypertrophic pyloric stenosis presents in up to 0.3% of newborns. In typical cases, nonbilious vomiting develops in the rst 4 weeks of life secondary to hypertrophy of the inner circular muscle of the pylorus with impaired sphincteric relaxation. There is a lack of inhibitory nerves in the pylorus, primarily those containing NO, and loss of the interstitial cells of Cajal.111,112 An enlarged pylorus (pyloric olive) can be palpated or detected radiologically. Treatment with surgical pyloromyotomy is effective, and patients usually remain symptom-free after surgery with resolution of the smooth muscle hypertrophy. Defects in interstitial cell numbers and NO transmission partially reverse after pyloromyotomy; however, pyloric tone may remain elevated with less frequent phasic pyloric pressure waves.113,114 Medical treatment with atropine has been proposed by some European groups. The condition also has been correlated with use of erythromycin for pertussis prophylaxis in neonates.115117 Hypertrophic pyloric stenosis in adults, not secondary to peptic ulcer disease or neoplasm, is exceedingly rare.118 Endoscopic dilation and laparoscopic pyloroplasty have occasionally been used as treatment.118,119 Generalized disorders of gastrointestinal motility. Gastroparesis may occur as a component of a denable generalized gut dysmotility syndrome. Chronic intestinal pseudo-obstruction is a syndrome with recurrent symptoms suggestive of intestinal obstruction in the absence of mechanical blockage. Radiologic ndings of chronic intestinal pseudo-obstruction include luminal dilation with air-uid levels throughout the small intestine. The term diffuse gastrointestinal motility disorder has been proposed if several gut regions exhibit delayed transit but have no luminal dilation or air-uid levels on radiographic examination.27 Chronic intestinal pseudo-obstruction can be caused by a variety of systemic diseases, including scleroderma, amyloidosis, myxedema, longstanding diabetes mellitus, and paraneoplastic complications most commonly seen with small cell lung carcinoma. However, many cases are idiopathic in nature. The 2 main forms of chronic intestinal pseudo-obstruction are myopathic and neuropathic. Small bowel manometry may assist in differentiating these 2 forms. In intestinal myopathy, low-amplitude contractions that propagate normally are seen. In intestinal neuropathy, contractions are normal in amplitude but disorganized in morphology, including disruption of phase III activity, bursts of nonpropagating activity during fasting, and failure to convert from the fasting to the postprandial fed motor pattern. Delayed gastric emptying is not uncommonly observed in patients with constipation. In one study, 19%
1602
of patients with primary constipation were found to have delayed gastric emptying.120 A second investigation of patients with irritable bowel syndrome observed delayed emptying of solids in 64% of patients, especially in those with constipation predominance.121 This has important implications for treatment because patients with chronic severe constipation with proximal gut dysmotility exhibit unsatisfactory responses to subtotal colectomy. Volitional suppression of defecation can also retard gastric emptying.122 Furthermore, colonic distention inhibits gastric motor function suggestive of a neurally mediated cologastric reex.
Nongastrointestinal disorders associated with delayed gastric emptying. Ischemic gastroparesis. Gastric
ischemia may occur as a consequence of chronic atherosclerotic disease. In many cases, gastric ischemia is insidious and difcult to recognize. Ischemic gastropathy secondary to atherosclerosis may present as gastritis, ulceration, or gastroparesis.123,124 Typically, the diagnosis is made angiographically. Surgical revascularization may improve gastric emptying and correct gastric dysrhythmias in affected patients.124 Malignancy-associated gastroparesis. Malignancy-associated gastroparesis has been described with esophageal, gastric, pancreatic, breast, and lung carcinoma. The pathophysiology is unknown but frequently is attributed to paraneoplastic effects, neural invasion by the tumor, or side effects of chemotherapy. In nonobstructing gastric cancers, tumor inltration into the stomach wall may disrupt coordinated smooth muscle or neural function. Delayed gastric emptying is reported in 40% 60% of patients with pancreatic adenocarcinoma. Usually gastroparesis secondary to pancreatic cancer is asymptomatic, but it may contribute to nausea, vomiting, abdominal pain, and pain radiating to the back in selected individuals.125 Gastroduodenal obstruction from the tumor, retroperitoneal nerve invasion from the tumor, or a paraneoplastic syndrome may all cause delayed gastric emptying in these patients. Intestinal pseudo-obstruction with delayed gastric emptying may be a paraneoplastic complication of malignancy, most commonly small cell lung carcinoma.126 Intestinal dysmotility is postulated to result from autoimmune destruction of myenteric neurons, because histologic studies have shown degeneration of the myenteric plexus with plasma cell and lymphocyte inltration.127 The onset of gut motor dysfunction may precede detection of the cancer.126 Antroduodenal manometry may show a typical neuropathic pattern of uncoordinated contractions of normal amplitude. A variety of autoimmune serologies may be detectable with paraneoplastic
pseudo-obstruction, including the type 1 antineuronal nuclear antibody (ANNA-1 or anti-Hu antibody).126 Delayed gastric emptying with nausea and vomiting can occur during treatment of malignancies. Gastroparesis can occur after abdominal radiation therapy,128 during treatment with chemotherapeutic agents,129 after bone marrow transplantation,130 and after celiac plexus blockade for chronic pain from pancreatic cancer.131 Chronic pancreatitis. In a retrospective series, 44% of patients with small-duct chronic pancreatitis had delayed gastric emptying.132 Some of the abdominal pain, nausea, and vomiting seen in patients with presumed or documented chronic pancreatitis may be due to gastroparesis. A recent study showed impaired gastric myoelectrical activity in chronic pancreatitis133; this abnormality was restored toward normal with replacement of pancreatic enzymes. Gastric emptying is variable in cystic brosis; it may be rapid early in the disease but delayed later in the disease.134 Renal failure. Patients on hemodialysis commonly report nausea, vomiting, anorexia, and early satiety. In one investigation, the degree of gastric emptying delay correlated with the magnitude of dyspeptic symptoms.135 A second study reported that the delay in solid gastric emptying is associated with changes in biochemical indicators of nutritional status.136 Infectious causes of gastroparesis. Delayed gastric emptying may occur with acute viral infection with varicella zoster, EpsteinBarr virus, cytomegalovirus, rotavirus, and parvovirus-like agents such as the Norwalk and Hawaii viruses.137,138 In most cases, the delay in gastric emptying is transient and resolves over time with recovery from the viral infection.106 Although reports largely are anecdotal, a small number of individuals develop chronic symptoms and comprise a subset of idiopathic gastroparesis.139,140 Gastric cytomegalovirus (CMV) infection most commonly presents in immunosuppressed individuals, particularly in those who have undergone organ transplantation.141 CMV infection of the upper gut is reported to occur in one third of patients after liver transplantation and produces typical symptoms of gastroparesis, including nausea and abdominal fullness. Endoscopy may show large antral folds, gastric inammation including acute supercial gastritis, and duodenal erosions and ulcerations. Viral cultures of gastric biopsy specimens and histologic demonstration of CMV inclusions in the gastric mucosa may provide the diagnosis.141 Gastrointestinal infection with CMV is unusual in immunocompetent individuals.139 Gastric emptying is delayed in one third of individuals seropositive for human immunodeciency virus, partic-
November 2004
1603
ularly in those with advanced disease evidenced by low CD4 counts, marked weight loss, and enteric infections.142,143 In many of these immunocompromised patients, the acute stage of gastritis and gastroparesis from viruses and other infectious agents, especially CMV and mycobacterium avium-intracellulare, may persist for prolonged periods. Some investigators have observed delayed emptying of solids with diminished postprandial antral motility and with coexistent rapid emptying of the liquids suggestive of an autonomic neuropathy secondary to human immunodeciency virus.144 The effects of Helicobacter pylori on gastric motor function have been the subject of controversy. Although a handful of studies have suggested an association with gastroparesis,145 most investigations observe no relationship between active H pylori infection and delayed gastric emptying or functional dyspepsia.146 Medication-induced gastroparesis. Nausea and vomiting are frequent side effects of medications and usually present early in their use. Thus, medications are considered to cause acute rather than chronic nausea and vomiting.24 Many medications, including anticholinergics, narcotics, tricyclic antidepressants, and calcium channel blockers, are known to delay gastric emptying (Table 3). Curiously, many acid-suppressive medications delay gastric emptying, although this effect is not likely to be of clinical relevance in most cases.147 Conversely, the histamine receptor antagonist nizatidine has been reported to exhibit weak prokinetic properties.148 Gastric emptying of solids is delayed in patients receiving total parenteral nutrition (TPN).149 As a result, some have advocated that the TPN formulation should be converted to intravenous saline during diagnostic evaluation of gastric emptying and antral motility.35 TPN-associated gastroparesis has been postulated to result from induction of hyperglycemia by the intravenous nutrient infusion. Intravenous infusion of fat emulsions also delays gastric emptying and may contribute to this phenomenon.149,150 Eating disorders. Anorexia nervosa is a psychiatric disorder occurring primarily in adolescent and young adult women that is characterized by distorted body image and fear of obesity with compulsive dieting and self-imposed starvation to maintain a profoundly low body weight. Gastrointestinal symptoms are prevalent in anorexia nervosa and include lack of appetite, early satiety, epigastric fullness, abdominal bloating, nausea, and vomiting.151,152 Patients with anorexia nervosa often exhibit delayed gastric emptying primarily for solids.152 Realimentation and restoration of normal body weight improve gastric emptying and symptoms.151,153 These observations suggest that the delay in gastric emptying is
secondary to the effects of pronounced weight loss with malnutrition or to the psychiatric issues that affect these women.151,153 Prokinetic drug therapy may improve gastric emptying and facilitate refeeding,152 although other studies have shown no effect on weight gain.154 Bulimia nervosa is characterized by recurrent episodes of binge eating, with a feeling of lack of control over the eating behavior during the binges, often followed by self-induced vomiting, the use of laxatives or diuretics, strict dieting or fasting, or vigorous exercise to prevent weight gain.155 Self-induced vomiting allows bulimic patients to continue eating or terminate the binge. In contrast to anorexia nervosa, concern about weight and body size does not lead to a decrease in weight below normal values. Most cases present in young women, with a peak age at onset of 18 years. Symptoms of postprandial fullness, early satiety, bloating, nausea, and epigastric pain may occur and may relate to the degree of associated depression.156 Gastric emptying studies in bulimia have shown conicting results as to the presence of gastroparesis.157,158 Therapy consists of cognitive-behavior therapy and pharmacotherapy to interrupt the binge-purge cycles.
Nongastrointestinal disorders that mimic gastroparesis. Rumination syndrome. Rumination syndrome re-
fers to the effortless regurgitation of recently ingested food into the mouth with subsequent remastication and reswallowing or expectoration of food. Initially described in children and mentally retarded institutionalized individuals, there is an increasing awareness of this disorder in adults of normal intelligence. Rumination can become a habit, often initiated by a belch, a swallow, or stimulation of the palate with the tongue. Abdominal muscle contraction with relaxation of the lower esophageal sphincter in the early postprandial period is responsible for regurgitation.159 Typically, the effortless repetitive regurgitation occurs within 15 minutes of beginning to eat, in contrast to vomiting in gastroparesis, which commonly occurs later in the postprandial period.51 The difculty in diagnosing rumination syndrome results from a lack of awareness of the disorder and the challenge in differentiating rumination from vomiting due to gastroparesis or regurgitation due to GERD. Results of gastric emptying studies and esophageal pH monitoring tests usually are normal. Gastroduodenal manometry may show characteristic transient simultaneous increases in gastric and small bowel pressure (R waves) in all abdominal recording ports during the postprandial period. These reect the effects of abdominal wall contraction. Treatment relies on behavioral modication and biofeedback therapy administered in a formal eating regulation program.160
1604
Cyclic vomiting syndrome. Cyclic vomiting syndrome is characterized by recurrent episodes of relentless nausea and vomiting lasting hours to days separated by symptom-free periods of variable lengths. The vomiting begins abruptly in most cases, although some individuals experience a prodrome of nausea and abdominal pain. The vomiting reaches its highest intensity during the rst hours, diminishes thereafter, and ends rapidly. The duration of vomiting averages 1 4 days and can result in marked dehydration. This disorder is much more prevalent in children, with a mean age at onset of 5 8 years, but recently has been described in adults.161,162 In adults, the vomiting episodes are longer (35 days) and less frequent (every 3 4 months) and triggering events are less evident.162 In most patients, ndings of gastric scintigraphy, antroduodenal manometry, and EGG are normal, suggesting that symptoms do not result from gastrointestinal dysmotility.163 Precipitating events, identied in a minority of patients, include onset of menstrual periods and stress. Cyclic vomiting syndrome is associated with migraine headaches.162 The underlying causes of cyclic vomiting syndrome are poorly understood. Other proposed etiologies include derangements of the hypothalamic-pituitary axis, inappropriate activation of the vomiting reex, and mitochondrial disorders.161,164 There are no uniformly effective therapies for cyclic vomiting syndrome. Sleep, a quiet environment, and the use of benzodiazepines such as lorazepam may be effective in some milder cases.162 Tricyclic antidepressants and -blockers may serve a prophylactic role, similar to their use in migraine therapy.162 Antiemetics such as the 5-HT3 receptor antagonist ondansetron and prokinetic agents such as metoclopramide or erythromycin can provide temporary relief during vomiting episodes. Antimigraine therapies such as the 5-HT1D receptor agonist sumatriptan may reduce the severity of attacks. Use of nonsteroidal anti-inammatory drugs such as indomethacin or intramuscular ketorolac have been reported to reduce the intensity of attacks, perhaps via their prostaglandin-inhibitory effects and their ability to reverse some gastric slow wave dysrhythmias.161 Functional vomiting. A number of patients present with nausea and vomiting of uncertain etiology and exhibit normal ndings on both structural and functional testing. The Rome II committee devised diagnostic criteria for functional vomiting, a condition that may share pathogenic features with other functional disorders, including functional dyspepsia and irritable bowel syndrome.165
Treatment of Symptomatic Gastroparesis

The general principles for treatment of symptomatic gastroparesis are to (1) correct uid, electrolyte, and nutritional deciencies; (2) identify and rectify the underlying cause of gastroparesis if possible; and (3) reduce symptoms.24 The patients medication list should be reviewed to eliminate drugs that might exacerbate the underlying dysmotility disorder or prevent the benecial actions of a prokinetic agent. Diabetic patients should strive for optimal glycemic control to minimize any inhibitory effects of hyperglycemia on gastric emptying. For relatively mild disease, dietary modications and a low-dose antiemetic or prokinetic agent might provide satisfactory control of symptoms. Patients with more severe manifestations of gastroparesis, such as refractory vomiting, pronounced dehydration, or chaotic glucose control, might require hospitalization, intravenous hydration, nasogastric suction to decompress the stomach, insulin for blood glucose control, and/or intravenous administration of antiemetic and prokinetic agents. As with the diagnostic approach to gastroparesis, most recommendations regarding its treatment are based on the cumulative experience and opinions of clinicians who specialize in the care of these patients. There is little in the way of controlled investigation to validate any therapeutic algorithm for the management of this challenging condition. Dietary Recommendations Dietary recommendations for the patient with gastroparesis rely on measures that promote gastric emptying, although few studies have been performed to validate this concept. Increasing the liquid nutrient component of the ingested meal should be emphasized because liquid emptying often is preserved in patients with gastroparesis who have delayed solid emptying. Fats and ber tend to retard emptying; thus, their intake should be minimized. Indigestible ber and roughage may predispose to bezoar formation. Meal size should be restricted because the stomach may only empty a given number of calories in a xed period of time.166 To compensate for small meal size, patients may need to eat 4 or 5 times daily. Carbonated beverages release carbon dioxide, which can aggravate gastric distention. High doses of alcohol can decrease antral contractility and impair gastric emptying.167 This also is true of tobacco smoking.168 Commercial or self-prepared liquid nutrient meals may be tolerated in small quantities. Larger volumes needed to cover daily caloric needs may exacerbate symp-
November 2004
1605
toms of gastroparesis. Enteral alimentation delivered into the small intestine may be helpful in patients with dysmotility restricted to the stomach. In some severe cases, TPN may be needed. Metabolic Control Diabetic patients with gastroparesis frequently exhibit labile blood glucose concentrations with prolonged periods of signicant hyperglycemia. Hyperglycemia itself delays gastric emptying even in the absence of xed gastric motor decits, which is likely mediated by reduced phasic antral contractility and induction of pyloric pressure waves.66,82 Hyperglycemia can inhibit the accelerating effects of prokinetic agents on gastric emptying.169 Improvement of glucose control increases antral contractility, corrects gastric dysrhythmias, and accelerates emptying. To date, there have been no longterm studies conrming the benecial effects of maintenance of near euglycemia on gastroparetic symptoms. Nevertheless, the consistent ndings of physiologic studies in healthy volunteers and diabetic patients provide a compelling argument to strive for near-normal blood glucose levels in affected diabetic patients. Antiemetic Agents Medications that act on peripheral and central neural structures as antiemetic agents provide the backbone for the treatment of many conditions with nausea and vomiting.24 Antiemetic drugs may serve as primary therapy for some patients with gastric dysmotility or as adjuncts to medications that promote gastric emptying. Phenothiazines are commonly prescribed antiemetic agents. These dopamine receptor antagonists act at the level of the area postrema of the medulla oblongata, a region termed the chemoreceptor trigger zone.24 Commonly used antiemetic agents include prochlorperazine, trimethobenzamide, and promethazine. Phenothiazines may be administered as tablets, capsules, liquid suspensions, or suppositories or by injection. For patients with severe symptoms, suppositories or injectable forms may be more efcacious. Side effects from phenothiazines are common and include sedation and extrapyramidal effects. Serotonin (5-HT3) receptor antagonists, including ondansetron, granisetron, and dolasetron, are useful for prophylaxis of chemotherapy-induced nausea and vomiting as well as symptoms occurring postoperatively or during radiation therapy. 5-HT3 antagonists may act both on the area postrema as well as on peripheral afferent nerve bers within the vagus.24 Although often used, there are no studies documenting their efcacy in
gastroparesis. If drugs in this class are considered, they are best given on an as-needed basis. Antihistamines acting on H1 receptors exhibit central antiemetic effects.24 Commonly prescribed antihistamines include diphenhydramine, dimenhydrinate, and meclizine. There is little evidence that antihistamines serve important roles in symptom control in gastroparesis. These agents are most useful for treatment of motion sickness via their actions on H1 receptors in the vestibular apparatus. In experimental motion sickness in healthy volunteers, dimenhydrinate reduced tachygastria, decreased symptoms, and evoked drowsiness, suggesting that symptom improvement may result from stabilization of gastric myoelectric rhythm or from depression of CNS activity.170 Transdermal hyoscine (scopolamine patch) is occasionally used for nausea and vomiting, primarily from motion sickness and recovery from anesthesia and surgery. This anticholinergic agent may delay gastric emptying. Benzodiazepines such as lorazepam and diazepam are most commonly used for the prevention of anticipatory nausea and vomiting before administration of chemotherapy.24 Cannabinoid drugs such as tetrahydrocannabinol have been studied for symptoms from chemotherapy and appear to have potency similar to standard antidopaminergics. A clear role in management of the patient with gastroparesis has not been established for either drug class. Prokinetic Agents Prokinetic medications enhance gut contractility and promote the aboral movement of luminal contents (Table 5). In the stomach, prokinetic agents increase antral contractility, correct gastric dysrhythmias, and improve antroduodenal coordination. Some prokinetics, including metoclopramide and domperidone, also exhibit antiemetic properties. Most commonly, motor stimulatory medications are administered 30 minutes before meals to elicit maximal clinical effects. Bedtime doses often are added to facilitate nocturnal gastric emptying of indigestible solids. Because symptom improvements correlate poorly with acceleration of gastric emptying, the response to treatment is usually judged clinically rather than following up with serial gastric emptying tests.171 Delayed gastric emptying is present in 20% 40% of patients with functional dyspepsia. Prokinetic medications, including metoclopramide, cisapride, and domperidone, have demonstrated utility in treating functional dyspepsia in placebo-controlled trials and in metaanalyses.172175 A recent meta-analysis suggested that favorable trials are selectively published, raising ques-
1606
Table 5. Prokinetic Agents for Gastroparesis

Agent Metoclopramide Mechanism of action Dopamine receptor antagonist central/peripheral Also 5-HT3 antagonist Also 5-HT4 agonist Motilin receptor agonist 5-HT4 receptor agonist facilitates acetylcholine release Also 5-HT3 antagonist Dopamine receptor antagonist peripheral 5-HT4 partial agonist Comments FDA approved for gastroparesis CNS side effects in 2030% Prokinetic and antiemetic properties Gastrointestinal side effects in many: nausea/vomiting/abdominal pain Tachyphylaxis with long-term oral administration Taken off market in March 2000 for prolonging QT interval Was only approved for nocturnal heartburn Currently not available as prescription in United States Prokinetic and antiemetic properties Available in Europe/Canada/Mexico/New Zealand but not in United States FDA approved for irritable bowel syndrome, constipation predominant in women Improves gastric emptying, no data on symptoms Increases amplitude of contractions, not peristalsis Not a true prokinetic agent
Erythromycin Cisapride
Domperidone Tegaserod
Bethanechol
Muscarinic receptor agonist
FDA, Food and Drug Administration.
tions about the true utility of prokinetics in functional dyspepsia.176 Metoclopramide. Metoclopramide, a substituted benzamide structurally related to procainamide, has been used for 35 years to treat gastroparesis. It exhibits both prokinetic and antiemetic actions.177 The drug releases acetylcholine from intrinsic myenteric cholinergic neurons via activation of 5-HT4 receptors and serves as a dopamine receptor antagonist in the stomach. It also exhibits weak 5-HT3 receptor antagonism.178 The prokinetic properties of metoclopramide are limited to the proximal gut. Metoclopramide increases esophageal, fundic, and antral contractile amplitudes, elevates lower esophageal sphincter pressure, and improves antropyloroduodenal coordination. Antidopaminergic actions in the area postrema explain the additional antiemetic actions. Metoclopramide is approved for use in diabetic gastroparesis and for prevention of postoperative and chemotherapy-induced nausea and vomiting. Controlled trials report that metoclopramide provides symptomatic relief while accelerating gastric emptying of solids and liquids in patients with idiopathic, diabetic, and postvagotomy gastroparesis and in patients with GERD (Table 6).179 187 Metoclopramide is effective for the short-term treatment of gastroparesis for up to several weeks.181,182 Symptomatic improvement does not necessarily accompany improvement in gastric emptying. Indeed, some investigations have reported extended symptom benets of metoclopramide without prolonged prokinetic action.188 The long-term utility of metoclopramide has not been proven.188 In diabetic patients with gastroparesis, gastric emptying is accelerated by short-term adminis-
tration of metoclopramide but not by long-term dosing for more than 1 month.189 The usual starting dose of metoclopramide in adults is 10 mg 30 minutes before meals and at bedtime. Dosing can be increased to 20 mg if the response to 10 mg is inadequate. For patients hospitalized for symptom exacerbations in gastroparesis, metoclopramide may be administered intravenously. The drug also can be taken in a liquid form. It has also been reported to be effective subcutaneously, by suppository, or even intraperitoneally in patients on peritoneal dialysis.190 The side effects from metoclopramide result from antidopaminergic actions in the CNS and may restrict its use in up to 30% of patients. Acute dystonic reactions such as facial spasm, oculogyric crisis, trismus, and torticollis occur in 0.2% 6% of patients; when this occurs, it is often observed within 48 hours of initiating therapy.191 Drowsiness, fatigue, and lassitude are reported by 10% of patients. Metoclopramide can aggravate underlying depression. Other side effects may include restlessness, agitation, irritability, and akathisia. Increased prolactin release may result in breast engorgement, lactation, and menstrual irregularity. Prolonged treatment with metoclopramide can produce Parkinsonian-like symptoms.191 Parkinsonian symptoms usually subside within 23 months following discontinuation of metoclopramide. Because of this effect, patients with Parkinsons disease should be given metoclopramide cautiously, if at all. Tardive dyskinesia, characterized by involuntary movements of the face, tongue, or extremities, may occur with prolonged use and may not reverse after stopping the medication. The prevalence of tardive dyskinesia ranges from 1% to 15% when taking metoclopramide for at least 3 months, and the complication has been reported to
November 2004
1607
Table 6. Systematic Review of Studies on Oral Metoclopramide for Treatment of Gastroparesis

Author/year/ reference Brownlee and Kroopf, 1974179 Longstreth et al, 1977180 Perkel et al, 1979181 Study design Open label, crossover Open label Randomized, double-blind, parallel group placebo controlled Randomized, double-blind, crossover placebo controlled No. of subjects 1 Types of patients Diabetic gastroparesis Dosage of metoclopramide 10 mg QID Length of study 5 mo Outcome results Improved symptoms Improved gastric emptying Improved symptoms Improved gastric emptying Improved symptoms by 29%
1 28
Diabetic gastroparesis Diabetic gastroparesis (5) Postsurgical gastroparesis (4) Idiopathic gastroparesis (19)
15 mg QID 10 mg QID
6 mo 3 wk
Snape et al, 1982182
10
Diabetic gastroparesis
10 mg QID
3 wk
McCallum et al, 1983183
Multicenter, placebo controlled Open label
18
10 mg QID
3 wk
Loo et al, 1984184
Diabetic gastropathy
10 mg QID
6 mo
Ricci et al, 1985185
Randomized
10 mg QID
3 wk
Erbas et al, 1993186
Randomized, single-blind, crossover Randomized, double-blind, multicenter
13
10 mg TID
3 wk
Patterson et al, 1999187
45
10 mg QID
4 wk
Improved symptoms in 7 of 10 by 56% Improved gastric emptying by 31% Poor correlation between gastric emptying and symptoms Improved symptom score by 25% Improved gastric emptying by 25% Improved symptoms in only 3 of 8 patients Side effects precluded treatment in many Improved symptoms in 52% Gastric emptying improved but did not correlate with symptom improvement Symptoms improved in 10 of 11 subjects by 62% Gastric emptying improved by 24% Symptoms improved by 39%
QID, 4 times a day; TID, 3 times a day.
occur with short-term use.191 Metoclopramide-evoked tardive dyskinesia is 3-fold more common in women than men.192 Erythromycin and motilides. The macrolide antibiotic erythromycin exerts prokinetic effects via action on gastroduodenal receptors for motilin, an endogenous peptide responsible for initiation of the MMC in the upper gut.193,194 When administered exogenously, motilin stimulates antral contractility and elicits premature antroduodenal phase III activity. Erythromycin binds to motilin receptors on smooth muscle and on cholinergic neurons, the latter of which appear to be important for actions.193,195 Erythromycin produces effects on gastroduodenal motility similar to motilin. Clinically, erythromycin has been shown to stimulate gastric emptying in diabetic gastroparesis, idiopathic
gastroparesis, and postvagotomy gastroparesis (Table 7).196 204 Indeed, the effects of erythromycin on gastric emptying are greater than observed with other prokinetic drugs. Interestingly, erythromycin accelerates emptying in postsurgical patients in whom the antrum, the primary site of its motor effect, has been resected.202 In these individuals, erythromycin may exert stimulatory effects on the fundus. Erythromycin may be most potent when used intravenously.205 In one investigation, treatment with intravenous erythromycin lactobionate (200 mg) markedly accelerated emptying of solids in patients with diabetic gastroparesis.196 In these same patients, 4 weeks of treatment with oral erythromycin ethylsuccinate (250 mg 30 minutes before meals) elicited much less potent stimulatory effects. Other studies performed over longer observation periods have reported reductions
1608
Table 7. Systematic Review of Studies on Oral Erythromycin and Motilides for Treatment of Gastroparesis
Author/year/reference Janssens et al, 1990196 Dull et al, 1990197 Study design Open label No. of subjects 10 Types of patients Diabetic gastroparesis Intervention Erythromycin 250 mg TID Erythromycin 200 mg TID Erythromycin 250 mg QID Erythromycin 200 mg QID Erythromycin 250 mg TID Length of study 4 wk Outcome results Improved symptoms and gastric emptying Improved symptoms and gastric emptying Improved symptoms Improved gastric emptying Improved symptoms and gastric emptying Symptoms improved in 11 of 13 patients by 75% Gastric emptying improved by 26% Symptoms improved in 7 of 10 patients by 20% Gastric emptying improved by 43% Symptoms improved in 3 of 9 patients by 15% Gastric emptying improved by 40% No overall improvement in symptoms (15% decrease, not signicant) No overall improvement in symptoms
Open label
Scleroderma gastroparesis
9 mo
Mozwecz et al, 1990198 Klutman and Eisenach, 1992199 Erbas et al, 1993200
Open label
Postvagotomy gastroparesis Idiopathic gastroparesis
2 wk
Open label
6 mo
Single-blind, randomized, crossover Open label
13
3 wk
Richards et al, 1993201
10
Diabetic gastroparesis (2) Erythromycin Idiopathic gastroparesis (8) 250 mg QID Postsurgical (total vagotomy and antrectomy) Diabetic gastroparesis Erythromycin 150 mg TID Erythromycin 250 mg TID ABT-229
4 wk
Ramirez et al, 1994202
Open label
2 wk
Samson et al, 1997203
Double-blind, placebo controlled, crossover Randomized, double blind, placebo controlled, parallel group
12
2 wk
Talley et al, 2001204
270
4 wk
TID, 3 times a day; QID, 4 times a day.
of benet over time with oral administration. Limited data exist concerning the clinical efcacy of erythromycin in reducing symptoms of gastroparesis (Table 7). In a systematic review of studies on oral erythromycin with symptom assessment as a clinical end point, improvement was noted in 43% of patients.206 One study comparing erythromycin and metoclopramide in an openlabel, crossover fashion in diabetic gastroparesis found similar efcacy.206 Oral administration of erythromycin should be initiated at low doses (eg, 125250 mg 3 or 4 times daily). Many physicians prefer using erythromycin liquid suspension because it is rapidly absorbed and facilitates dosage modications.207 Intravenous erythromycin (100 mg every 8 hours) is used for inpatients hospitalized for severe refractory gastroparesis.208 Side effects of erythromycin at higher doses include nausea, vomiting, and abdominal pain. Because these symptoms may mimic those of gastroparesis, erythromycin may have a narrow therapeutic window in some patients. Hyperglycemia attenuates the stimulation of antral contractility and gastric emptying by erythromycin.169
Investigators have searched for macrolide compounds that activate motilin receptors but do not exhibit the antimicrobial effects of erythromycin. One such motilide compound, ABT-229, was not effective for relief of postprandial dyspeptic symptoms in diabetic gastroparesis or functional dyspepsia.204,209 Others are now being tested. Domperidone. Domperidone is a benzimidazole derivative and is a specic dopamine (D2) receptor antagonist. The effects of domperidone on the upper gut are similar to those of metoclopramide, including stimulation of antral contractions and promotion of antroduodenal coordination (Table 8).8,210 218 Domperidone does not readily cross the blood-brain barrier; therefore, it is much less likely to cause extrapyramidal side effects than metoclopramide.217 In addition to prokinetic actions in the stomach, domperidone exhibits antiemetic properties via action on the area postrema, a brainstem region with a porous blood-brain barrier. Domperidone has been studied primarily in patients with diabetic gastroparesis, in whom it increases both solid and liquid emptying.212 Symptomatic improvement with domperidone does not clearly relate to its
November 2004
1609
Table 8. Systematic Review of Studies on Oral Domperidone for Treatment of Gastroparesis

Author/year/reference Nagler and Miskovitz, 1981210 Watts et al, 1985211 Horowitz et al, 1985212 Study design Randomized, placebo controlled Open label Open label No. of subjects 3 Type of patients Diabetic gastroparesis Dosage of Length of domperidone study 10 mg QID 4 wk Outcome results Symptoms improved in 2 of 3 patients Symptoms improved Gastric emptying improved Symptoms improved in 11 of 12 patients No change in gastric emptying of solids, decrease in gastric emptying of liquids Improved symptoms Improved gastric emptying by 37%
3 12
Diabetic gastroparesis Diabetic gastropathy
10 mg QID 20 mg TID
6 mo 12 mo
Champion et al, 1987213
Davis et al, 1988214
Koch et al, 19898
Double-blind, placebo controlled, parallel group Double-blind, randomized, placebocontrolled Open label
19
20 mg QID
4 wk
Idiopathic gastroparesis
20 mg QID
6 wk
Symptoms improved in 7 of 9 patients by 36% No change in gastric emptying Symptoms improved in 5 of 6 patients Gastric emptying improved in 4 of 6, not signicant Symptom score improved by 68% Gastric emptying improved by 34% Symptoms improved in 208/269 patients by 63% Symptom score improved by 41% (similar efcacy to metoclopramide but less side effects) Symptoms improved Gastric emptying improved by 27% (better than metoclopramide)
20 mg QID
6 mo
Soykan et al, 1997215 Open label
17
Silvers et al, 1998216 Single-blind Patterson et al, 1999217 Multicenter, randomized, double blind Double-blind
287 48
Idiopathic gastroparesis (12) Diabetic gastroparesis (3) Postsurgical gastroparesis (2) Diabetic gastropathy Diabetic gastropathy
20 mg QID
2y
20 mg QID 20 mg QID
4 wk 4 wk
Dumitrascu and Weinbeck, 2000218
10
10 mg TID
N/A
QID, 4 times a day; TID, 3 times a day.
motor stimulatory actions; rather, its efcacy may stem from its antiemetic effects.8,217 In controlled clinical trials, domperidone provided relief of symptoms and improvement in quality of life to greater degrees than placebo in patients with diabetic gastropathy; symptom improvement was similar to that observed for metoclopramide and cisapride but with fewer CNS side effects.217 Furthermore, symptomatic diabetic patients with normal gastric emptying reported benecial effects with domperidone therapy.214 The prokinetic actions of domperidone may be transitory in nature. At 6 weeks, the effect of domperidone on solid-phase gastric emptying was lost, while that on liquid emptying was maintained.212 Another investigation reported persistent reductions in nausea and vomiting after 6 weeks of treatment with no acceleration of solid gastric emptying.214 Other studies report that improvements in gastric emptying and symptoms were still present after 1 year of treatment.215 Domperidone has been advocated for ther-
apy of nausea and vomiting in patients with Parkinsons disease, in whom symptoms may be secondary to gastroparesis or to dopaminergic drugs used to treat the disease (eg, L-dopa).215 Dosing of domperidone typically begins at 10 mg before meals and at bedtime and can be increased as tolerated to achieve symptom control. In many patients, the dose of domperidone can be more easily increased to improve symptom control because of the near lack of neuropsychiatric and extrapyramidal side effects. The most common side effects of domperidone relate to induction of hyperprolactinemia, with induction of menstrual irregularities, breast engorgement, and galactorrhea. An intravenous formulation of domperidone was removed in the 1980s due to generation of cardiac arrhythmias. Domperidone is not approved by the Food and Drug Administration (FDA) for prescription in the United States, although it can be obtained in Canada, Mexico, New Zealand, Europe, and Japan. In the United
1610
States, the drug had been prepared in capsules by compounding pharmacies.219 Recently, an investigational new drug (IND) application can now be opened by physicians through the FDA to provide domperidone to patients with gastroparesis refractory to other therapies. Tegaserod. Tegaserod, an aminoguanidine indole compound, is a partial 5-HT4 receptor agonist approved for the treatment of constipation-predominant irritable bowel syndrome. In healthy volunteers, tegaserod stimulates interdigestive small intestinal motility and postprandial antral and intestinal motility.220 Tegaserod has been shown to accelerate gastric emptying in some221 but not all studies of healthy volunteers.222 In unpublished studies, tegaserod was shown to accelerate solid-phase gastric emptying in patients with gastroparesis in dose-dependent fashion, with 6 mg 3 times daily and 12 mg twice daily showing greater effect than the standard dose for constipation (6 mg twice daily).223 Effects of tegaserod on symptoms have not been reported in patients with gastroparesis. However, tegaserod has a marginal effect on symptoms in functional dyspepsia with some improvement in early satiety and postprandial fullness.224 Other prokinetic agents. Bethanechol is a nonspecic cholinergic muscarinic receptor agonist. It enhances amplitude of contractions throughout the gastrointestinal tract. Unfortunately, bethanechol does not elicit coordinated contractions and acceleration of gastric emptying and small bowel transit is not reliably demonstrated. As a consequence, bethanechol is not a true prokinetic agent.225 Rarely, the drug may be helpful as an adjunct with other prokinetic medications in patients refractory to standard treatment with prokinetic and antiemetic drugs. The typical dose is 25 mg orally 4 times daily. Side effects of bethanechol are prominent and include increased salivation, blurred vision, abdominal cramps, and bladder spasm. Acetylcholinesterase inhibitors, such as physostigmine and neostigmine, stimulate gut motor activity by increasing acetylcholine levels with subsequent muscarinic receptor activation. As with bethanechol, anticholinesterase agents do not improve antroduodenal coordination and have inconsistent effects on gastric emptying.226 In animal studies, gut transit is accelerated at lower doses but inhibited at higher doses.227 This dual effect may be related to activation of different muscarinic receptor subtypes. Their utility in gastroparesis has not been studied. Cisapride is a 5-HT4 receptor agonist that facilitates release of acetylcholine from myenteric cholinergic nerves throughout the gut.24 Cisapride stimulates antral
and duodenal contractions, improves antroduodenal coordination, and accelerates gastric emptying.44,72 Cisapride accelerates gastric emptying and decreases symptoms in patients with gastroparesis, an effect that may last for 1 year. Cisapride was approved by the FDA for nocturnal heartburn in patients with GERD. However, postmarketing surveillance identied a number of cases of cardiac arrhythmias and sudden death.24,225 These effects were not due to the 5-HT4 agonist properties of cisapride but rather were a direct action of cisapride on cardiac potassium channels, which prolonged the QT interval and predisposed patients to development of ventricular arrhythmias, including torsades de pointes. As a consequence, cisapride was withdrawn from the US market in 2000. It is only available under compassionateuse/limited-access programs with strict patient monitoring through Janssen Pharmaceutica.219 Its use is strongly discouraged in individuals with underlying cardiac disease, especially of the conduction system, and in patients on medications known to affect the QT interval. Management of Refractory Gastroparesis There is no consensus regarding management of patients with gastroparesis who do not respond to simple antiemetic or prokinetic therapy or who develop severe medication-induced side effects. In one investigation of 110 patients with refractory gastroparesis, 74% responded to use of another prokinetic agent while only 26% were refractory to all prokinetic agents.1 Patients with gastroparesis who did not respond to prokinetic therapy were usually postgastrectomy patients, those with myopathic connective tissue disorders, those with type 1 diabetes mellitus with profoundly delayed gastric emptying, and those with idiopathic gastroparesis with abdominal pain. Managing the patient with refractory gastroparesis includes ensuring that gastroparesis is responsible for symptoms, optimizing current therapy, and changing prokinetic agents if maximal doses of the current treatment program are inadequate.225 It is unclear why some patients respond to one prokinetic agent and not another. Refractory patients often require treatment with both prokinetic and antiemetic agents. For patients who are truly refractory to all attempts at pharmacotherapy of gastroparesis, placement of a feeding jejunostomy and/or venting gastrostomy can be considered. Use of TPN should be temporary if possible due to the risk of complications. Newer therapies being evaluated are pyloric injection of botulinum toxin and gastric electric stimulation. Gastric resection usually is of limited value for most etiologies of gastroparesis.
November 2004
1611
Combination prokinetic therapy. Prokinetic agents act via different mechanisms to enhance gastric emptying (Table 5). Theoretically, addition of a second prokinetic agent may augment the response of the rst drug if the 2 agents act on different receptor subtypes. Dual prokinetic therapy with domperidone and cisapride has been reported to accelerate emptying and reduce symptoms in some patients with refractory gastroparesis.228 Combinations of available prokinetic agents in the United States, such as metoclopramide and erythromycin, have not been specically studied. Psychotropic medications. Tricyclic antidepressants may have signicant benets in suppressing symptoms in some patients with nausea and vomiting as well as patients with abdominal pain.229 In one retrospective analysis, tricyclic antidepressants reduced symptoms in patients with functional vomiting.230 In 2 recent studies in functional dyspepsia and one in diabetic gastropathy, low-dose tricyclic antidepressants decreased dyspeptic symptoms and abdominal pain.231,232 In an unpublished retrospective evaluation of diabetic patients with nausea and vomiting, tricyclic antidepressants provided better symptom reduction than prior trials of antiemetic and prokinetic drugs.233 In this study, nearly one third of patients exhibited delayed gastric emptying, suggesting that the presence of impaired motor function is not necessarily a contraindication to use of this drug class. Doses of tricyclic antidepressants used are lower than used to treat depression. A reasonable starting dose for a tricyclic drug is 10 25 mg at bedtime. If benet is not observed in several weeks, doses are increased by 10- to 25-mg increments up to 50 100 mg. Side effects are common with use of tricyclic antidepressants and can interfere with management and lead to a change in medication in 25% of patients.229 The secondary amines, nortriptyline and desipramine, may have fewer side effects. There are limited data on the use of selective serotonin reuptake inhibitors in gastroparesis or functional dyspepsia. Pyloric botulinum toxin injection. Gastric emptying is a highly regulated process reecting the integration of the propulsive forces of proximal fundic tone and distal antral contractions with the functional resistance provided by the pylorus. Manometric studies of patients with diabetic gastroparesis show prolonged periods of increased pyloric tone and phasic contractions, a phenomenon termed pylorospasm.45 One unpublished investigation has reported symptom benets with surgical pyloromyotomy in patients with diabetic gastroparesis.234 Botulinum toxin is a potent inhibitor of neuromuscular transmission and has been used to treat spastic somatic muscle disorders as well as achalasia.235 Several
studies have tested the effects of pyloric injection of botulinum toxin in patients with diabetic and idiopathic gastroparesis (Table 9).236 242 These studies have all been unblinded in small numbers of patients from single centers and have observed mild improvements in gastric emptying and modest reductions in symptoms for several months. Double-blind controlled studies are needed to support the efcacy of this treatment. Gastric electric stimulation. Gastric electric stimulation is an emerging treatment for refractory gastroparesis (Table 10).243249 There are several techniques for stimulating the stomach. Electrical stimulation at a frequency 10% higher than that of the intrinsic slow wave entrains and paces gastric myoelectric activity with high-energy, long-duration pulses. This technique has been reported to accelerate gastric emptying and improve dyspeptic symptoms in a small uncontrolled series.244 More recently, an implantable neurostimulator that delivers a high-frequency (12 cpm), low-energy signal with short pulses has been studied in patients with idiopathic and diabetic gastroparesis. The higher-frequency stimulus does not entrain slow waves or reverse underlying slow wave dysrhythmias. With this device, stimulating wires are sutured into the gastric muscle along the greater curvature during laparoscopy or laparotomy. These leads are attached to the electric stimulator, which is positioned in a subcutaneous abdominal pouch. An initial study showed effectiveness in 20 of 26 patients, with decreases in nausea and vomiting at 3 and 6 months.248 In this investigation, gastric neurostimulation promoted gastric emptying of liquids but not solids. In long-term follow-up, 3 patients underwent total gastrectomy due to unsatisfactory results and 3 required device removal secondary to erosion or infection. A second study of 33 patients with chronic gastroparesis consisted of an initial double-blind sham stimulation-controlled trial for 2 months followed by an open phase in which the device was activated for 1 year.249 During the blinded phase of the investigation, patients felt better when the stimulator was turned on with a small but signicant reduction in vomiting frequency. The improvement was seen primarily in patients with diabetic rather than idiopathic gastroparesis. Long-term follow-up over 1 year showed a decrease in the mean vomiting frequency from 25 to 6 times per week with an associated improvement in quality of life. Subsequent studies have reported improvements in nutritional parameters and decreased requirements for supplemental feedings.250 Some open-label studies have not shown benet.251 The main complication of the implantable neurostimulator has been infection, which has necessitated device removal in approximately 5%10% of cases.
1612
Table 9. Systematic Review of Studies on Botulinum Toxin Injection Into the Pyloric Sphincter for Treatment of Gastroparesis
Author/year/ reference Sharma et al, 1998236 Lacy et al, 2000237 Muddasani and Ismail-Beigi, 2001238 Ezzeddine et al 2002239 No. of subjects 1 Dose of botulinum toxin 80 U Length of study 4 mo
Study design Open label
Types of patients Diabetic gastroparesis
Outcome results Symptoms improved Gastric emptying improved by 33% Symptoms improved Symptoms improved Gastric emptying improved by 43% Symptoms decrease by 55% at 2 and 6 weeks Gastric emptying improved by 43% at 2 and 6 weeks Symptoms improved by 58% One half of patients had improvement in gastric emptying Symptoms improved by 38% at 1 month Gastric emptying improved by 48% at 1 month Many required subsequent treatments over 6month follow-up Symptoms improved by 29% at 1 month Gastric emptying of solids improved by 35% at 1 month
Open label Open label
3 1
Diabetic gastroparesis Diabetic gastroparesis
200 U 200 U
410 wk 4.5 mo
Open label
100 U
6 wk
Lacy et al, 2002240
Open label
200 U
12 wk
Miller et al, 2002241
Open label
10
Idiopathic gastroparesis
80100 U
4 wk
Arts et al, 2003242
Open label
20
Diabetic gastroparesis (3) Idiopathic gastroparesis (17)
100 U
1 mo
Because of potential benets, the gastric electric neurostimulator was granted humanitarian approval from the FDA for the treatment of chronic, refractory nausea and vomiting secondary to idiopathic or diabetic gastroparesis. Presently, reimbursement for implantation of this device is obtained by petitioning third-party payers on an individual basis. Further investigation is needed to conrm the effectiveness of gastric stimulation in longterm blinded fashion, which patients are likely to respond, the optimal electrode position, and the optimal stimulation parameters, none of which have been rigorously evaluated to date. Future improvements may include devices that sequentially stimulate the stomach in a peristaltic sequence to promote gastric emptying.252 Gastrostomy and jejunostomy placement. In refractory patients with severe nausea and vomiting, placement of a gastrostomy tube for intermittent decompression by venting or suctioning may provide symptom relief, especially of interdigestive fullness and bloating secondary to retained intragastric gas and liquids. This approach also has been suggested for patients with refractory vomiting that responds to nasogastric decompression.253 Venting gastrostomies may be placed endo-
scopically, surgically, or by interventional radiology. In one series, symptoms were reduced, patients gained weight, and 6 of 8 patients were able to return to full-time work or school.254 For patients with gastroparesis who are unable to maintain nutrition with oral intake, placement of a feeding jejunostomy may decrease symptoms and reduce hospitalizations.255 Jejunostomy tubes are effective for providing nutrition, uids, and medications if there is normal small intestinal motor function.255,256 Except in cases of profound malnutrition or electrolyte disturbance, enteral feedings are preferable to chronic parenteral nutrition because of the signicant risks of infection and liver disease with the latter treatment, especially in diabetic patients. In contrast, home intravenous hyperalimentation may be needed for individuals with generalized dysmotility unresponsive to dietary and medication management. The therapeutic response to jejunostomy infusion may be predicted by a trial of nasojejunal feedings,253 which should precede placement of a permanent jejunostomy tube if small bowel dysmotility is suspected. Jejunostomy tubes usually are surgically placed during laparoscopy or laparotomy, although a few centers
November 2004
1613
Table 10. Systematic Review of Studies on Gastric Electric Stimulation for Treatment of Gastroparesis
Author/year/ reference Study design No. of subjects 1 Types of patients Diabetic gastroparesis Intervention Gastric electric stimulation (high frequency, low amplitude) Gastric pacing (low frequency, high amplitude) Length of study 1y Outcome results Symptoms improved Gastric emptying improved Symptoms decreased by 46% Gastric emptying improved by 26% Improved symptoms by 34% Gastric emptying improved in 14 of 21, not signicant Symptoms improved in 14 of 15 patients
Familoni et Open label al, 1997243 McCallum et Open label al, 1998244
Diabetic gastroparesis (5) Idiopathic gastroparesis (3) Postsurgical gastroparesis (1)
1 mo
Forster et al, 2001245
Open label
25
Diabetic gastroparesis (19) Gastric electric stimulation Idiopathic gastroparesis (3) (high frequency, low Postsurgical gastroparesis (3) amplitude)
12 mo
Sobrino et al, Open label 2002246
15
Skole et al, 2002247 Abell et al, 2002248 Abell et al, 2003249
Open label
11
Diabetic gastroparesis (9) Idiopathic gastroparesis (5) Postvagotomy gastroparesis (1) Diabetic gastroparesis (7) Idiopathic gastroparesis (4)
Gastric electric stimulation (high frequency, low amplitude)
7.3 mo
Open label, multicenter Double-blind, multicenter
38
33
Gastric electric stimulation (high frequency, low amplitude) Idiopathic gastroparesis (24) Gastric electric stimulation Diabetic gastroparesis (9) (high frequency, low Postsurgical gastroparesis (5) amplitude) Diabetic gastroparesis (17) Gastric electric stimulation Idiopathic gastroparesis (16) (high frequency, low amplitude)
6 mo
Symptoms improved in 6 of 11 patients Symptoms improved in 33 of 38 patients Improved symptoms Double blind: symptoms decreased by 15% Open label: symptoms decreased by 39% Gastric emptying improved by 19%
24 wk 11 mo 1 mo 12 mo
place these endoscopically.257 Nutrient feedings are started at low infusion rates of 20 mL/h with diluted nutrient meals and advanced slowly (increase of 10 mL/h every 12 hours) until the goal of daily nutritional intake is obtained with iso-osmolar infusions. Glucose levels should be checked frequently in diabetic patients, with provision for supplemental insulin as necessary. Carefully regulated enteral nutrient infusion may improve glycemic control in diabetic patients with refractory vomiting.256 Nocturnal feedings only may permit daytime working and functioning. Complications include infection, tube dysfunction, and tube dislodgment.253,255 Surgical treatment of gastroparesis. There are limited controlled data concerning surgical treatment of diabetic or idiopathic gastroparesis.253 In general, most uncontrolled studies report disappointing responses to operative resection in these patients.24 Surgery is performed only as a last resort in carefully evaluated patients with profound gastric stasis.253 The procedure usually used is a partial gastrectomy with Roux-en-Y gastrojejunostomy. Subtotal gastrectomy (70%) with resection of antrum and pylorus, closure of the duodenum, and restoration of gastrointestinal continuity with a 60-cm Roux-en-Y jejunal loop has been reported to be of benet in 2 small studies of 4 and 7 patients with type 1
diabetes mellitus who had gastroparesis and intractable vomiting, although 3 of the 7 patients in the second series developed renal failure and 2 died within 5 months of surgery.79,258 Gastric resection may be a more viable therapy for selected patients with postsurgical gastroparesis who are unresponsive to treatment with prokinetic or antiemetic drugs or in whom complications such as malnutrition or aspiration develop. These patients may require this radical surgery to eliminate stasis in an atonic stomach and creation or revision of a Roux limb to prevent enterogastric reux. Most commonly, the remainder of the stomach is resected (completion gastrectomy), leaving only a small rim ( 1 cm) of proximal stomach for construction of an anastomosis.259,260 A Roux limb of at least 45 cm to the rim of the stomach is constructed. Studies have suggested that this extensive surgery leads to improvement in 43% 67% of patients.259,261,262 The combination of nausea, the need for TPN, and the presence of retained food at endoscopy predicted a poor outcome. Reports of completion gastrectomy for postsurgical gastroparesis are uncontrolled case series or retrospective reviews; prospective investigation is warranted to conrm the benets of this operation.253
1614
Pancreas transplants and simultaneous kidney-pancreas transplants are being increasingly performed for patients with type 1 diabetes mellitus. With successful pancreatic transplantation, postprandial hyperglycemia resolves and treatment with insulin can be discontinued.263 Simultaneous kidney-pancreas transplantation may correct both uremia and hyperglycemia. Pancreatic transplantation has been shown to halt progression and slightly improve diabetic peripheral polyneuropathy.264 The literature is sparse concerning effects on gastric emptying. One study reported improvement in gastric emptying of liquids in 6 of 8 patients with previously delayed emptying but no improvement in emptying of solids 6 months after transplantation.263 Another study observed improved emptying in 8 of 23 patients 1 year after kidneypancreas transplantation.265 Some investigators reported improved symptoms and improved gastric dysrhythmias in diabetic patients after transplantation despite minimal acceleration of emptying.263,265 New Directions in the Treatment of Gastric Dysmotility Syndromes
Novel prokinetic agents. New prokinetic agents being tested for gastroparesis include 5-HT4 receptor agonists (tegaserod and mosapride), dopamine receptor antagonists (levosulpiride), cholecystokinin receptor antagonists (dexloxiglumide), and motilin receptor agonists (mitemcinal [GM-611]). Levosulpiride, with both antiemetic and prokinetic effects, may relieve symptoms and accelerate gastric emptying in diabetic patients with gastroparesis.266 Loxiglumide, a cholecystokinin-A receptor antagonist, increases antral contractility and accelerates gastric emptying in healthy subjects, suggesting possible utility in gastroparesis.267 Fundic relaxing agents. Agents that relax the fundus and improve accommodation may be helpful in some patients with gastroparesis and functional dyspepsia, especially when early satiety is prominent. 5-HT1 receptor agonists (sumatriptan, buspirone),268 -adrenergic receptor agonists (clonidine), and NO donors (nitroglycerin) have been evaluated in physiologic studies.269 Clonidine reduces proximal gastric tone and pain perception with gastric distention in healthy subjects.269 In dyspeptic patients, clonidine reduces symptoms by improving gastric accommodation.269 Clonidine has been reported to decrease symptoms and accelerate gastric emptying in diabetic patients with gastroparesis, although others have observed slowing of emptying with the drug.270,271 The 5-HT1 agonists evoke fundic relaxation through an NO-mediated pathway.268 Sumatriptan
allows accommodation of larger volumes before perception or discomfort is reached and improves meal-induced satiety in patients with functional dyspepsia.268 Buspirone, another oral 5-HT1 agonist, has anxiolytic properties in addition to its fundic relaxant capabilities. Unpublished observations suggest that sildenal augments gastric accommodation by enhancing the effects of NO.272 In an animal study, sildenal promoted pyloric relaxation and accelerated gastric emptying.81 However, a subsequent investigation in rats reported that sildenal delayed liquid gastric emptying and small bowel transit and an unpublished study in humans also observed delay of gastric emptying.273 Gastric slow wave antidysrhythmics. Many prokinetic drugs (metoclopramide, domperidone, cisapride) also stabilize dysrhythmic slow wave activity in patients with gastroparesis.8,274 In some studies, resolution of slow wave rhythm disturbances correlates better with symptomatic improvement than does acceleration of gastric emptying.8 Prostaglandin inhibitors have been shown to resolve tachygastrias during hyperglycemia.85 In some patients, indomethacin has reduced symptoms and reversed gastric myoelectrical abnormalities.275 Unfortunately, indomethacin is also ulcerogenic.
Alternative and unconventional medical therapies. Complementary therapies and alternative medi-
cines are used frequently by patients with gastroparesis and functional dyspepsia. Ginger, a traditional Chinese herbal remedy, reduces nausea and associated tachygastria caused by experimental motion sickness. Ginger also reduces hyperglycemia-induced gastric dysrhythmias and nausea.276 Psychodynamic interpersonal psychotherapy and hypnotherapy have been reported to be helpful in functional dyspepsia.277,278 Biofeedback and hypnotic techniques to accelerate gastric emptying in gastroparetic patients are being explored.279 Stimulation of the PC6 point on the wrist with acupuncture, electroacupuncture, electrical stimulation, or acupressure may control postoperative nausea, chemotherapyinduced nausea, and nausea during the rst trimester of pregnancy.280 283 The Zusanli point (ST36) located below the patella is another site of acupuncture stimulation with effects on gastric motility.284 Animal studies suggest that electroacupuncture accelerates gastric emptying by stimulation of vagal pathways.283 Electroacupuncture is postulated to modulate serotonin, substance P, and endogenous opioid pathways in the CNS.285 Naloxone, an opioid receptor antagonist, blocks the analgesic effect of acupuncture and worsens symptoms of motion sickness.285
November 2004
1615
Conclusion
This report has reviewed the diagnosis and treatment of gastroparesis. Several tests are available for the evaluation of patients with suspected gastroparesis. Treatments of gastric dysmotility rely on dietary, pharmacologic, and surgical therapies that relieve symptoms and maintain adequate nutrition. This is an area of active investigation because the current therapy is suboptimal and existing treatments have not been well studied. Evidence-based investigation will be required to better dene appropriate approaches to this challenging condition. HENRY P. PARKMAN Temple University School of Medicine Philadelphia, Pennsylvania WILLIAM L. HASLER University of Michigan Medical Center Ann Arbor, Michigan ROBERT S. FISHER Temple University School of Medicine Philadelphia, Pennsylvania
References
1. Soykan I, Sivri B, Sarosiek I, Kierran B, McCallum RW. Demography, clinical characteristics, psychological proles, treatment and long-term follow-up of patients with gastroparesis. Dig Dis Sci 1998;43:2398 2404. 2. Parkman HP, Schwartz SS. Esophagitis and other gastrointestinal disorders associated with diabetic gastroparesis. Arch Intern Med 1987;147:14771480. 3. Blum ME, Lichtenstein GR. A new endoscopic technique for the removal of gastric phytobezoars. Gastrointest Endosc 2000;52: 404 408. 4. Stanghellini V, Tosetti C, Paternico A, Barbara G, Morselli-Labate AM, Monetti N, Marengo M, Corinaldesi R. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996;110:1036 1042. 5. Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003;98: 783788. 6. Revicki DA, Rentz AM, Dubois D, Kahrilas P, Stanghellini V, Talley NJ, Tack J. Development and validation of a patientassessed gastroparesis symptoms severity measure: the Gastroparesis Cardinal Symptom Index. Aliment Pharmacol Ther 2003;18:141150. 7. Horowitz M, Harding PE, Maddox AF, Wishart JM, Akkermans LM, Chatterton BE, Shearman DJ. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32:151159. 8. Koch KL, Stern RM, Stewart WR, Vasey MW. Gastric emptying and gastric myoelectrical activity in patients with diabetic gastroparesis: effect of long-term domperidone treatment. Am J Gastroenterol 1989;84:1069 1075. 9. Talley NJ, Shuter B, McCrudden G, Jones M, Hoschl R, Piper DW. Lack of association between gastric emptying of solids and symptoms in nonulcer dyspepsia. J Clin Gastroenterol 1989;11: 625 630.
10. Jones KL, Russo A, Stevens JE, Wishart JM, Berry MK, Horowitz M. Predictors of delayed gastric emptying in diabetes. Diabetes Care 2001;24:1264 1269. 11. Jian R, Ducrot F, Ruskone A, Chaussade S, Rambaud JC, Modigliani R, Rain JD, Bernier JJ. Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. Dig Dis Sci 1989;34:657 664. 12. Hoogerwerf WA, Pasricha PJ, Kalloo AN, Schuster MM. Pain: the overlooked symptom in gastroparesis. Am J Gastroenterol 1999;94:1029 1033. 13. Lemann M, Dederding JP, Flourie B, Franchisseur C, Rambaud JC, Jian R. Abnormal perception of visceral pain in response to gastric distension in chronic idiopathic dyspepsia. Dig Dis Sci 1991;36:1249 1254. 14. Samsom M, Salet GAM, Roelofs JMM, Akkermans LM, Vanberge-Henegouwen GP, Smout AJ. Compliance of the proximal stomach and dyspeptic symptoms in patients with type 1 diabetes mellitus. Dig Dis Sci 1995;40:20372042. 15. Datz FL. Christian PE, Moore J. Gender-related differences in gastric emptying. J Nucl Med 1987;28:1204 1207. 16. Gill RC, Murphy PD, Hooper HR, Bowes KL, Kingma YJ. Effect of the menstrual cycle on gastric emptying. Digestion 1987;36: 168 174. 17. Bytzer P, Talley NJ, Leemon M, Young LJ, Jones MP, Horowitz M. Prevalence of gastrointestinal symptoms associated with diabetes mellitus. Arch Intern Med 2001;161:1989 1996. 18. Maleki D, Locke GR, Camilleri M, Zinsmeister AR, Yawn BP, Leibson C, Melton J III. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med 2000;160:2808 2816. 19. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/ International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol 1999;34(Suppl 231):48 54. 20. Farup CE, Williams GR, Leidy NK, Helbers L, Murray M, Quigley EMM. Effect of domperidone on the health-related quality of life of patients with symptoms of diabetic gastroparesis. Diabetes Care 1998;21:1699 1706. 21. Bell RA, Jones-Vessey K, Summerson JH. Hospitalizations and outcomes for diabetic gastroparesis in North Carolina. South Med J 2002;95:12971299. 22. Abell TL, Luo J, Cutts TF, Mealer W, Kores R, Rashed H. Gastric electrical stimulation is superior to standard pharmacological treatment in reducing health care costs and hospital stays and in improving quality of life in patients with severe upper GI motor disorders (abstr). Am J Gastroenterol 2001;235:s258. 23. Botoman VA, Rao S, Dunlap P, Abell T, Falk GW. Motility and GI function studies billing and coding guidelines. Am J Gastroenterol 2003;98:1228 1236. 24. Quigley EMM, Hasler W, Parkman HP. AGA technical review on nausea and vomiting. Gastroenterology 2001;120:263286. 25. Herlinger H. Guide to imaging of the small bowel. Gastroenterol Clin North Am 1995;24:309 329. 26. Hornbuckle K, Barnett JL. The diagnosis and work-up of the patient with gastroparesis. J Clin Gastroenterol 2000;30:117 124. 27. Parkman HP, Harris AD, Krevsky B, Urbain JL, Maurer AH, Fisher RS. Gastroduodenal motility and dysmotility: update on techniques available for evaluation. Am J Gastroenterol 1995;90: 869 892. 28. Malagelada J-R, Rees WDW, Mazzotta LJ, Go VL. Gastric motor abnormalities in diabetic and postvagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology 1980;78:286 293. 29. Galil MA, Critchley M, Mackie CR. Isotope gastric emptying tests in clinical practice: expectation, outcome, and utility. Gut 1993; 34:916 919.
1616
30. Tougas GH, Eaker EY, Abell TL, Abrahamsson H, Boivin PL, Chen J, Hocking MP, Quigley EM, Koch KL, Tokayer AZ, Stanghellini V, Chen Y, Huizinga JD, Ryden J, Bourgeois I, McCallum RW. Assessment of gastric emptying using a low fat meal: establishment of international control values. Am J Gastroenterol 2000; 95:1456 1462. 31. Kim D-Y, Myung S-J, Camilleri M. Novel testing of human gastric motor and sensory functions: Rationale, methods, and potential applications in clinical practice. Am J Gastroenterol 2000;95: 33653373. 32. Lartigue S, Bizais Y, Des Varannes SB, Murat A, Pouliquen B, Galmiche JP. Inter- and intrasubject variability of solid and liquid gastric emptying parameters. A scintigraphic study in healthy subjects and diabetic patients. Dig Dis Sci 1994;39:109 115. 33. Thomforde GM, Camilleri M, Phillips SF, Forstrom LA. Evaluation of an inexpensive screening scintigraphic test of gastric emptying. J Nucl Med 1995;36:9396. 34. Guo J-P, Maurer AH, Fisher RS, Parkman HP. Extending gastric emptying scintigraphy from two to four hours detects more patients with gastroparesis. Dig Dis Sci 2001;46:24 29. 35. Camilleri M, Hasler W, Parkman HP, Quigley EM, Soffer E. Measurement of gastroduodenal motility in the GI laboratory. Gastroenterology 1998;115:747762. 36. Ghoos YF, Maes BD, Geypens BJ, Mys G, Hiele MI, Rutgeerts PJ, Vantrappen G. Measurement of gastric emptying rate of solids by means of a carbon-labeled octanoic acid breath test. Gastroenterology 1993;104:1640 1647. 37. Choi M-G, Camilleri M, Burton DD, Zinsmeister AR, Forstrom LA, Nair KS. Reproducibility and simplication of 13C-octanoic acid breath test for gastric emptying of solids. Am J Gastroenterol 1998;93:9298. 38. Bromer MQ, Kantor SN, Wagner DA, Knight LC, Maurer AH, Parkman HP. Simultaneous measurement of gastric emptying with a simple mufn meal using 13C-octanoate breath test and scintigraphy in normal subjects and patients with in dyspeptic symptoms. Dig Dis Sci 2002;47:16571663. 39. Chen JZ, McCallum RW. Clinical applications of electrogastrography. Am J Gastroenterol 1993;88:1324 1336. 40. Parkman HP, Hasler WL, Barnett JL, Eaker EY. Electrogastrography: a document prepared by the gastric section of the American Motility Society Clinical GI Motility Testing Task Force. Neurogastroenterol Motil 2003;15:488 497. 41. Chen JD, Lin Z, Pan J, McCallum RW. Abnormal gastric myoelectrical activity and delayed gastric emptying in patients with symptoms suggestive of gastroparesis. Dig Dis Sci 1996;41: 1538 1545. 42. Parkman HP, Miller MA, Trate DM, Knight LC, Brown KL, Maurer AH, Fisher RS. Electrogastrography and gastric emptying scintigraphy are complementary for assessment of dyspepsia. J Clin Gastroenterol 1997;24:214 219. 43. Jebbink RJA, Samsom M, Bruijs PPM, Bravenboer B, Akkermans LM, Van Berge-Henegouwen GP, Smout AJ. Hyperglycemia induces abnormalities of gastric myoelectrical activity in patients with type 1 diabetes mellitus. Gastroenterology 1994;107: 1390 1397. 44. Fraser RJ, Horowitz M, Maddox AF, Dent J. Postprandial antropyloroduodenal motility and gastric emptying in gastroparesis effects of cisapride. Gut 1994;35:172178. 45. Mearin F, Camilleri M, Malagelada J-R. Pyloric dysfunction in diabetics with recurrent nausea and vomiting. Gastroenterology 1986;90:1919 1925. 46. Dooley CO, el Newihi HM, Zeidler A, Valenzuela JE. Abnormalities of the migrating motor complex in diabetics with autonomic neuropathy and diarrhea. Scand J Gastroenterol 1988;23:217 223.
47. Camilleri M, Malagelada J-R. Abnormal intestinal motility in diabetics with the gastroparesis syndrome. Eur J Clin Invest 1984;14:420 427. 48. Camilleri M, Brown ML, Malagelada J-R. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986;91:94 99. 49. Camilleri M. Study of human gastroduodenojejunal motility applied physiology in clinical practice. Dig Dis Sci 1993;38: 785794. 50. Frank JW, Sarr MG, Camilleri M. Use of gastroduodenal manometry to differentiate mechanical and functional intestinal obstruction: an analysis of clinical outcome. Am J Gastroenterol 1994;89:339 344. 51. OBrien MD, Bruce BK, Camilleri M. The rumination syndrome: clinical features rather than manometric diagnosis. Gastroenterology 1995;108:1024 1029. 52. Hyman PE, DiLorenzo C, McAdams L, Flores AF, Tomomasa T, Garvey TO. Predicting the clinical response to cisapride in children with chronic intestinal pseudo-obstruction. Am J Gastroenterol 1993;88:832 836. 53. Verne GN, Eaker EY, Hardy E, Sninsky CA. Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci 1995;40:18921901. 54. Soffer E, Thongsawat S. Clinical value of duodenojejunal manometry. Its usefulness in diagnosis and management of patients with gastrointestinal symptoms. Dig Dis Sci 1996;41: 859 863. 55. Benini L, Sembenini C, Heading RC, Giorgetti PG, Montemezzi S, Zamboni M, DiBenedetto P, Brighenti F, Vantini L. Simultaneous measurement of gastric emptying of a solid meal by ultrasound and by scintigraphy. Am J Gastroenterol 1999;94:28612865. 56. Kuiken SD, Samsom M, Camilleri M, Mullan BP, Burton DD, Kost CJ, Hardyman TJ, Brinkmann BH, OConnor MK. Development of a test to measure gastric accommodation in humans. Am J Physiol 1999;277:G1217G1221. 57. Kim D-Y, Delgado-Aros S, Camilleri M, Samsom M, Murray JA, OConnor MK, Brinkman BH, Stephens DH, Lighuani SS, Burton DD. Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol 2001;96:3099 3105. 58. Koch KL, Hong S-P, Xu L. Reproducibility of gastric myoelectrical activity and the water load test in patients with dysmotility-like dyspepsia symptoms and in control subjects. J Clin Gastroenterol 2000;31:125129. 59. Tack J, Caenepeel P, Piessevaux H, Cuomo R, Janssens J. Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia. Gut 2003;52:12711277. 60. Chial HJ, Camilleri M, Delgado-Aros S, Burton D, Thomforde G, Ferber I, Camilleri M. A nutrient drink test to assess maximum tolerated volume and postprandial symptoms: effects of gender, body mass index and age in health. Neurogastroenterol Motil 2002;14:249 253. 61. Kong M-F, Horowitz M, Jones KL, Wishart JM, Harding PE. Natural history of diabetic gastroparesis. Diabetes Care 1998;22: 503507. 62. Nowak TV, Johnson CP, Kalbeisch JH, Roza AM, Wood CM, Weisbruch JP. Highly variable gastric emptying in patients with insulin dependent diabetes mellitus. Gut 1995;37:2329. 63. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT. Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 1996;19:468 471. 64. Frank JW, Saslow SB, Camilleri M, Thomforde GM, Dinneen S, Rizza RA. Mechanism of accelerated gastric emptying of liquids and hyperglycemia in patients with type II diabetes mellitus. Gastroenterology 1995;109:755765.
November 2004
1617
65. Horowitz M, Harding PE, Maddox AF, Maddern GJ, Collings PH, Chatterton BE, Wishart J, Shearman DJC. Gastric and oesophageal emptying in insulin-dependent diabetes mellitus. J Gastroenterol Hepatol 1986;1:97113. 66. Rayner CK, Samsom M, Jones KL, Horowitz M. Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001;24:371381. 67. Ishii K, Tanabe S, Mitsuhashi T, Saigenji K. Inuence on glycemic control of improved diabetic gastroparesis by long-term cisapride therapy. Nippon Shokakibyo Gakkai Zasshi 1995;92: 1724 1733. 68. Stacher G, Schernthaner G, Francesconi M, Kopp HP, Bergmann H, Stacher-Janotta G, Weber U. Cisapride versus placebo for 8 weeks on glycemic control and gastric emptyng in insulin-dependent diabetes: a double blind cross-over trial. J Clin Endocrinol Metab 1999;84:23572362. 69. Pan DY, Chen GH, Chang CS, Ho KS, Poon SK, Huang CK, Kao CH, Wang SJ. Effect of oral erythromycin on patients with diabetic gastroparesis. Zhonghua Yi Xue Za Zhi (Taipei) 1995;55: 447 471. 70. Melga P, Mansi C, Ciuchi E, Giusti R, Sciaba L, Prando R. Chronic administration of levosulpiride and glycemic control in IDDM patients with gastroparesis. Diabetes Care 1997;20:55 58. 71. Ueno N, Inui A, Asakawa A, Takao F, Tani S, Komatsu Y, Itoh Z, Kasuga M. Erythromycin improves glycaemic control in patients with type II diabetes mellitus. Diabetologia 2000;43:411 415. 72. Braden B, Enghofer M, Schaub M, Usadel KH, Caspary WJ, Lembcke B. Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. Aliment Pharmacol Ther 2002;16:13411346. 73. Lehmann R, Honegger RA, Feinle C, Fried M, Spinas GA, Schwizer W. Glucose control is not improved by accelerating gastric emptying in patients with type 1 diabetes mellitus and gastroparesis. A pilot study with cisapride as a model drug. Exp Clin Endocrinol Diabetes 2003;111:255261. 74. Yoshida MM, Schufer MD, Sumi SM. There are no morphologic abnormalities of the gastric wall or abdominal vagus in patients with diabetic gastroparesis. Gastroenterology 1988;94:907 914. 75. Duchen LW, Anjorin A, Watkins PJ, Mackay JD. Pathology of autonomic neuropathy in diabetes mellitus. Ann Intern Med 1980;92:301303. 76. Takahashi T, Nakamura K, Itoh H, Sima AA, Owyang C. Impaired expression of nitric oxide synthase in gastric myenteric plexus of spontaneously diabetic rats. Gastroenterology 1997;113: 15351544. 77. Ordog T, Takayama I, Cheung WK, Ward SM, Sanders KM. Remodeling of networks of interstitial cells of Cajal in a murine model of diabetic gastroparesis. Diabetes 2000;49: 17311739. 78. He CL, Soffer EE, Ferris CD, Walsh RM, Szurszewski JH, Farrugia G. Loss of interstitial cells of Cajal and inhibitory innervation in insulin-dependent diabetes. Gastroenterology 2001;121:427 434. 79. Ejskjaer NT, Bradley JL, Buxton-Thomas MS, Edmons HE, Howard ER, Purewa IT, Thomas PK, Watkins RJ. Novel surgical treatment and gastric pathology in diabetic gastroparesis. Diabetic Med 1999;16:488 495. 80. Moscoso GJ, Driver M, Guy RJ. A form of necrobiosis and atrophy of smooth muscle in diabetic gastric autonomic neuropathy. Pathol Res Pract 1986;181:188 194. 81. Watkins CC, Sawa A, Jaffrey S, Blackshaw S, Barrow RK, Snyder SH, Ferris CD. Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy. J Clin Invest 2000;106:373384.
82. Fraser RJ, Horowitz M, Maddox AF, Harding PE, Chatterton BE, Dent J. Hyperglycemia slows gastric emptying in type 1 (insulindependent) diabetes mellitus. Diabetologia 1990;33: 675 680. 83. Lam WF, Masclee AAM, de Boer SY, Lamers CB. Hyperglycemia reduces gastric secretory and plasma pancreatic polypeptide responses to modied sham feeding in humans. Digestion 1993;54:48 53. 84. Mizuno Y, Oomura Y. Glucose responding neurons in the nucleus tractus solitarius of the rat: in vitro study. Brain Res 1984;307:109 116. 85. Hasler WL, Soudah HC, Dulai G, Owyang C. Mediation of hyperglycemia-evoked gastric slow-wave dysrhythmias by endogenous prostaglandins. Gastroenterology 1995;108:727736. 86. Jones KL Horowitz M, Berry M, Wishart JM, Guha S. Blood glucose concentrations inuences postprandial fullness in IDDM. Diabetes Care 1997;29:11411146. 87. Eagon JC, Miedema BW, Kelly KA. Postgastrectomy syndromes. Surg Clin North Am 1992;72:445 465. 88. Mathias JR, Fernandez A, Sninsky CA, Clech MH, Davis RH. Nausea, vomiting, and abdominal pain after Roux-en-Y anastomosis: motility of the jejunal limb. Gastroenterology 1985;88: 101107. 89. Vassilakis JS, Xynos E, Kasapidis P, Chrysos E, Mantides A, Nicolopoulos N. The effect of oppy Nissen fundoplication on esophageal and gastric motility in gastroesophageal reux. Surg Gynecol Obstet 1993;177:608 616. 90. Bais JE, Samsom M, Boudesteijn EA, van Rijk PP, Akkermans LM, Gooszen HG. Impact of delayed gastric emptying on the outcome of antireux surgery. Ann Surg 2001;234:139 146. 91. Haque M, Pehlivanov N, Moncure M, Udobi K, Childs E, Sarosiek I, McCallum R. Is there a shift in symptomatology in patients after laparoscopic Nissen fundoplication? (abstr). Am J Gastroenterol 2001;96:S66. 92. Stanghellini V, Malagelada J-R. Gastric manometric abnormalities in patients with dyspeptic symptoms after fundoplication. Gut 1983;24:790 797. 93. Hunter RJ, Metz DC, Morris JB, Rothstein RD. Gastroparesis: a potential pitfall of laparoscopic Nissen fundoplication. Am J Gastroenterol 1996;91:26172618. 94. Trus TL, Bax T, Richardson WS, Branum GD, Mauren SJ, Swanstrom LL, Hunter JG. Complications of laparoscopic paraesophageal hernia repair. J Gastrointest Surg 1997;1:221228. 95. DeVault KR, Floch NR, Achem SR, Hinder RA. Vagal nerve dysfunction before and after antireux surgery (abstr). Am J Gastroenterol 2001;96:S10. 96. Lundell LR, Myers JC, Jamieson GG. Delayed gastric emptying and its relationship to symptoms of gas bloat after antireux surgery. Eur J Surg 1994;160:161166. 97. Mun EC, Blackburn GL, Matthews JB. Current status of medical and surgical therapy for obesity. Gastroenterology 2001;120: 669 681. 98. Horowitz M, Cook DJ, Collins PJ, Harding PE, Hooper MJ, Walsh JF, Shearman DJC. Measurement of gastric emptying after gastric bypass surgery using radionuclides. Br J Surg 1982;69: 655 657. 99. Balsiger BM, Poggio JL, Mai J, Kelly KA, Sarr MG. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. J Gastrointest Surg 2000;4:598 605. 100. Mistiaen W, Vaneerdeweg W, Blockx P, Van Hee R, Hubens G, Bortier H, Harrisson F. Gastric emptying rate measurement after vertical banded gastroplasty. Obes Surg 2000;10:245249. 101. Berkowitz N, Schulman LL, McGregor C, Markowitz D. Gastroparesis after lung transplantpotential role in postoperative respiratory complications. Chest 1995;108:16021607. 102. Au J, Hawkins T, Venables C, Morritt G, Scott CD, Gascoigne AD, Corris PA, Hilton CJ, Dark JH. Upper gastrointestinal dysmotility
1618
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.
114.
115.
116.
117.
118.
119.
120.
121.
in heart-lung transplant recipients. Ann Thorac Surg 1993;55:94 97. Sodhi SS, Guo J-P, Maurer AH, OBrien G, Srinivasan R, Parkman HP. Delayed gastric emptying after combined heart and lung transplantation. J Clin Gastroenterol 2002;34:34 39. Zarate N, Mearin F, Wang XY, Hewlett B, Huizinga JD, Malagelada JR. Severe idiopathic gastroparesis due to neuronal and interstitial cells of Cajal degeneration: pathological ndings and management. Gut 2003;52:966 970. Bityutskiy LP, Soykan I, McCallum RW. Viral gastroparesis: a subgroup of idiopathic gastroparesis clinical characteristics and long-term outcomes. Am J Gastroenterol 1997;92:1501 1506. Oh JJ, Kim CH. Gastroparesis after a presumed viral illness: clinical and laboratory features and natural history. Mayo Clin Proc 1990;65:636 642. McCallum RW, Berkowitz DM, Lerner E. Gastric emptying in patients with gastroesophageal reux. Gastroenterology 1981; 80:285291. Keshavarzian A, Bushnell DL, Sontag S, Yegelwel EJ, Smid K. Gastric emptying in patients with severe reux esophagitis. Am J Gastroenterol 1991;86:738 742. Stacher G, Lenglinger J, Bergmann H, Schneider C, Hoffmann W, Wol G, Stacher-Janotta G. Gastric emptying: a contributory factor in gastro-oesophageal reux activity? Gut 2000;47:661 666. Barnert JRA, Dumitrascu DL, Wienbeck M. Gastroesophageal reux disease: Emptying of the proximal and the distal stomach measured by ultrasonography (abstr). Gastroenterology 2001; 120:A460. Vanderwinden J-M, Mailleux P, Schiffmann SN, Vanderhaeghen J-J, de Laet M-H. Nitric oxide synthase activity in infantile hypertrophic pyloric stenosis. N Engl J Med 1992;327:511515. Vanderwinden J-M, Liu H, de Laet M-H, Vanderhaeghen J-J. Study of the interstitial cells of Cajal in infantile hypertrophic pyloric stenosis. Gastroenterology 1996;111:279 288. Vanderwinden J-M, Liu H, Menu R, Conreur J-L, de Laet M-H, Vanderhaeghen J-J. The pathology of infantile hypertrophic pyloric stenosis after healing. J Pediatr Surg 1996;31:1530 1534. Sun WM, Doran SM, Jones KL, Davidson G, Dent J, Horowitz M. Long-term effects of pyloromyotomy on pyloric motility and gastric emptying in humans. Am J Gastroenterol 2000;95:92100. Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L, Correa A, Hall S, Erickson JD. Infantile hypertrophic stenosis after pertussis prophylaxis with erythromycin. Lancet 1999;354:21012105. SanFilippo A. Infantile hypertrophic pyloric stenosis related to ingestion of erythromycin estolate: a report of ve cases. J Pediatr Surg 1976;11:177180. Anonymous. Hypertrophic pyloric stenosis in infants following pertussis prophylaxis with erythromycinKnoxville, Tennessee, 1999. MMWR 1999;48:11171120. van Roggen JFG, van Krieken JHJM. Adult hypertrophic pyloric stenosis: case report and review of the literature. J Clin Pathol 1998;51:479 480. Danikas D, Geis WP, Ginalis EM, Stratoulias C. Laparoscopic pyloroplasty in idiopathic hypertrophic pyloric stenosis in an adult. JSLS 2000;4:173175. Bonapace ES, Davidoff S, Krevsky B, Fisher RS, Parkman HP. Whole gut transit scintigraphy in the clinical evaluation of patients with upper and lower gastrointestinal symptoms. Am J Gastroenterol 2000;95:2838 2847. Caballero-Plasencia AM, Valenzuela-Barranco M, HerreriasGutierrez JM, Esteban-Carretero JM. Altered gastric emptying in patients with irritable bowel syndrome. Eur J Nucl Med 1999; 26:404 409.
122. Tjeerdsma HC, Smout AJPM, Akkermans LMA. Voluntary suppression of defecation delays gastric emptying. Dig Dis Sci 1993;38:832 836. 123. Casey KM, Quigley TM, Kozarek RA, Raker EJ. Lethal nature of ischemic gastropathy. Am J Surg 1993;165:646 649. 124. Liberski SM, Koch KL, Atnip RG, Stern RM. Ischemic gastroparesis: resolution after revascularization. Gastroenterology 1990;99:252257. 125. Sikora SS, Mital BR, Prasad KR, Das BK, Kaushik SP. Functional gastric impairment in carcinoma of the pancreas. Br J Surg 1995;82:11121113. 126. Lee H-R, Lennon VA, Camilleri M, Prather CM. Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics. Am J Gastroenterol 2001;96:373379. 127. Schufer MD, Baird HW, Fleming CR, Bell CE, Bouldin TW, Malagelada JR, McGill DB, LeBauer SM, Abrams M, Love J. Intestinal pseudo-obstruction as the presenting manifestation of small-cell carcinoma of the lung. Ann Intern Med 1983;98: 129 134. 128. Layer P, Demol P, Hotz J, Goebell H. Gastroparesis after radiationsuccessful treatment with carbachol. Dig Dis Sci 1986; 31:13771380. 129. Brand RE, DiBaise JK, Quigley EMM, Gobar LS, Harmaon KS, Lynch JC, Bierman PJ, Bishop MR, Tarantolo SR. Gastroparesis as a cause of nausea and vomiting after high-dose chemotherapy and haemopoietic stem-cell transplantation. Lancet 1998; 352:1985. 130. Eagle DA, Gian V, Lauwers GY, Manivel JC, Moreb JS, Mastin S, Wingard JR. Gastroparesis following bone marrow transplantation. Bone Marrow Transplant 2001;28:59 62. 131. Iftikhar S, Loftus EV. Gastroparesis after celiac plexus block. Am J Gastroenterol 1998;93:22232225. 132. Chowdhury RS, Forsmark CE, Davis RH, Toskes PP, Verne GN. Prevalence of gastroparesis in patients with small duct chronic pancreatitis. Pancreas 2003;26:235238. 133. Lu C-L, Chen C-Y, Chang F-Y, et al. Impaired gastric myoelectrical activity in patients with chronic pancreatitis (abstr). Dig Dis Sci 2001;46:692. 134. Collins CE, Francis JL, Thomas P, Henry RL, OLoughlin EV. Gastric emptying time is faster in cystic brosis. J Pediatr Gastroenterol Nutr 1997;25:492 498. 135. Van Vlem B, Schoonjans R, Vanholder R, De Vos M, Vandamme W, Van Laecke S, Lameire N. Delayed gastric emptying in dyspeptic chronic hemodialysis patients. Am J Kidney Dis 2000; 36:962968. 136. De Schoenmakere G, Vanholder R, Rottey S, Duym P, Lameire N. Relationship between gastric emptying and clinical and biochemical factors in chronic haemodialysis patients. Nephrol Dial Transplant 2001;16:1850 1855. 137. Kebede D, Barthel JS, Singh A. Transient gastroparesis associated with cutaneous herpes zoster. Dig Dis Sci 1987;32:318 322. 138. Meeroff JC, Schreiber DS, Trier JS, Blacklow NR. Abnormal gastric motor function in viral gastroenteritis. Ann Intern Med 1980;92:370 373. 139. Nowak TV, Goddard M, Batteiger B, Cummings OW. Evolution of acute cytomegalovirus gastritis to chronic gastrointestinal dysmotility in a nonimmunocompromised adult. Gastroenterology 1999;116:953958. 140. Vassallo M, Camilleri M, Caron BL, Low PA. Gastrointestinal motor dysfunction in acquired selective cholinergic dysautonomia associated with infectious mononucleosis. Gastroenterology 1991;100:252258. 141. Van Thiel DH, Gavaler JS, Schade RR, Chien MC, Starzl TE. Cytomegalovirus infection and gastric emptying. Transplantation 1992;54:70 73.
November 2004
1619
142. Corley DA, Cello JP, Koch J. Evaluation of upper gastrointestinal tract symptoms in patients infected with HIV. Am J Gastroenterol 1999;94:2890 2896. 143. Neild PJ, Nijran KS, Yazaki E, Evans DF, Wingate DL, Jewkes R, Gazzard BG. Delayed gastric emptying in human immunodeciency virus infection. Dig Dis Sci 2000;45:14911499. 144. Konturek JW, Fischer H, Van Der Voort IR, Domschke W. Disturbed motor activity in patients with human immunodeciency virus infection. Scand J Gastroenterol 1997;32:221225. 145. Mearin F, de Ribot X, Balboa A, Salas A, Varas MJ, Cucala M, Bartolome R, Armengol JR, Malagelada JR. Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia? Gut 1995;37:4751. 146. Tucci A, Corinaldesi R, Stanghillini V, Tosetti C, DiFebo G, Paparo GF, Varoli O. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 1992;103:768 774. 147. Parkman HP, Urbain J-LC, Knight LC, Brown KL, Trate DM, Miller MA, Maurer AH, Fisher RS. Effect of gastric acid suppressants on human gastric motility. Gut 1998;42:243250. 148. Ueki S, Seiki M, Yoneta T, Aita H, Chaki K, Hori Y, Morita H, Tagashira E, Itoh Z. Gastroprokinetic activity of nizatidine, a new H2-receptor antagonist, and its possible mechanism of action in dogs and rats. J Pharmacol Exp Ther 1993;264:152157. 149. Masclee AAM, Gielkens AJ, Lam WF, de Boer SY, Lamers CB. Effects of parenteral nutrients on gastrointestinal motility and secretion. Scand J Gastroenterol 1996;31(Suppl 218):50 55. 150. Casaubon PR, Dahlstrom KA, Vargas J, Hawkins R, Mogard M, Ament ME, Masci L. Intravenous fat emulsion (Intralipid) delays gastric emptying, but does not cause gastroesophageal reux in healthy volunteers. J Parenter Enteral Nutr 1989;13:246 248. 151. Wasdholtz BD, Anderson AE. Gastrointestinal symptoms in anorexia nervosaa prospective study. Gastroenterology 1990; 98:14151419. 152. McCallum RW, Grill BB, Lange R, Planky M, Glass EE, Greeneld DG. Denition of a gastric emptying abnormality in patients with anorexia nervosa. Dig Dis Sci 1985;30:713722. 153. Rigaud D, Bedig G, Merrouche M, Vulpillat M, Bonls S, Apfelbaum M. Delayed gastric emptying in anorexia nervosa is improved by completion of a renutrition program. Dig Dis Sci 1988;33:919 925. 154. Szmukler GI, Young GP, Lichtensein M, Andrews JT. A serial study of gastric emptying in anorexia and bulimia. Aust N Z J Med 1990;20:220 225. 155. Mehler PS. Bulimia nervosa. N Engl J Med 2003;349:875 881. 156. Chami TN, Andersen AE, Crowell M, Schuster MM, Whitehead WE. Gastrointestinal symptoms in bulimia nervosa: effects of treatment. Am J Gastroenterol 1995;90:88 92. 157. Kiss A, Bergmann H, Abatzi Th-A, Schneider C, Wiesnagrotzki S, Hobart J, Steiner-Mittelbach G, Gaupmann G, Kugi A, StacherJanotta G, Steinringer H, Stacher G. Oesophageal and gastric motor activity in patients with bulimia nervosa. Gut 1990;31: 259 265. 158. Hutson WR, Wald A. Gastric emptying in patients with bulimia nervosa and anorexia nervosa. Am J Gastroenterol 1990 Jan; 85:41 46. 159. Thumshirn M, Camilleri M, Hanson RB, Williams DE, Schei AJ, Kammer PP. Gastric mechanosensory and lower esophageal sphincter function in rumination syndrome. Am J Physiol 1998; 275:G314 G321. 160. Malcolm A, Thumshirn MB, Camilleri M, Williams DE. Rumination syndrome. Mayo Clin Proc 1997;72:646 652. 161. Pasricha PJ, Schuster MM, Saudek CD, Wand G, Ravich WJ. Cyclic vomiting: association with multiple homeostatic abnormalities and response to ketorolac. Am J Gastroenterol 1996; 91:2228 2232.
162. Prakash C, Clouse RE. Cyclic vomiting syndrome in adults: clinical features and response to tricyclic antidepressants. Am J Gastroenterol 1999;94:28552860. 163. Abell TL, Kim CH, Malagelada J-R. Idiopathic cyclic nausea and vomitinga disorder of gastrointestinal motility? Mayo Clin Proc 1988;63:1169 1175. 164. Boles RG, Williams JC. Mitochondrial disease and cyclic vomiting syndrome. Dig Dis Sci 1999;44:103S107S. 165. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada J-R, Tytgat GNJ. Functional gastroduodenal disorders. In: Drossman DA, ed. Rome II: the functional disorders. Degnon Associates, McLean, VA, 2000. 166. Moore JG, Christian PE, Coleman RE. Gastric emptying of varying meal weight and composition in man. Dig Dis Sci 1981;26: 16 22. 167. Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol 2000;95:3374 3382. 168. Miller G, Palmer KR, Smith B, Ferrington C, Merrick MV. Smoking delays gastric emptying of solids. Gut 1989;30:50 53. 169. Petiakis IE, Vrachassotakis N, Sciacca V, Vassilakis SI, Chalkiadakis G. Hyperglycemia attenuates erythromycin-induced acceleration of solid phase gastric emptying in idiopathic and diabetic gastroparesis. Scand J Gastroenterol 1999;34:396 403. 170. Muth ER, Jokerst M, Stern RM, Koch KL. Effects of dimenhydrinate on gastric tachyarrhythmia and symptoms of vection-induced motion sickness. Aviat Space Environ Med 1995;66: 10411045. 171. Talley NJ. Diabetic gastropathy and prokinetics. Am J Gastroenterol 2003;98:264 271. 172. Veldhuyzen van Zanten SJO, Cleary C, Talley NJ, Peterson TC, Nyren O, Bradley LA, Verlinden M, Tytgat GN. Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996;91:660 673. 173. Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsiaa meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989;11:169 177. 174. Finney JS, Kinnersley N, Hughes M, OBryan-Tear CG, Lothian V. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998;26:312320. 175. Veldhuyzen van Zanen SJOV, Jones MJ, Verlinden M, Talley NJ. Efcacy of cisapride and domperidone in functional (non ulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001;96:689 696. 176. Soo S, Deeks JJ, Delaney BC, Moayyedi P, Innes M, Forman D. A systematic review of pharmacological therapies in non-ulcer dyspepsia (abstr). Gastroenterology 2000;118:A440. 177. Longstreth GF, Malagelada J-R, Kelly KA. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann Intern Med 1977;86:195196. 178. Clarke DE, Craig DA, Fozard JR. The 5-HT4 receptor: naughty, but nice. TIPS 1989;10:385390. 179. Brownlee M, Kroopf SS. Metoclopramide for gastroparesis diabeticorum. N Engl J Med 1974;291:12571258. 180. Longstreth GF, Malagelada J-R, Kelly KA. Metoclopramide stimulation of gastric motility and emptying in diabetic gastroparesis. Ann Intern Med 1977;186:195196. 181. Perkel MS, Moore C, Hersh T, Davidson ED. Metoclopramide therapy in patients with delayed gastric emptying. Dig Dis Sci 1979;24:662 666. 182. Snape WJ, Battle WM, Schwartz SS, Braunstein SN, Goldstein HA, Alavi A. Metoclopramide to treat gastroparesis due to diabetes mellitus. Ann Intern Med 1982;96:444 446. 183. McCallum RW, Ricci DA, Rakatansky H, Behar J, Rhodes JB, Salen G, Daren J, Ippoliti A, Olsen HS, Falchuk K, Hersh T. A
1620
184.
185.
186.
187.
188. 189.
190.
191.
192.
193. 194.
195.
196.
197.
198.
199. 200.
201.
202.
multicenter placebo-controlled clinical trial of oral metoclopramide in diabetic gastroparesis. Diabetes Care 1983;6:463 467. Loo FD, Palmer DW, Soergel KH, Kalbeisch JH, Wood CM. Gastric emptying in patients with diabetes mellitus. Gastroenterology 1984;86:485 494. Ricci DA, Saltzman MB, Meyer C, Callachan C, McCallum RW. Effect of metoclopramide in diabetic gastroparesis. J Clin Gastroenterol 1985;7:2532. Erbas T, Varoglu E, Erbas B, Tastekin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993;16:15111514. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A doubleblind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230 1234. Lata PF, Pigarelli DL. Chronic metoclopramide therapy for diabetic gastroparesis. Ann Pharmacother 2003;37:122126. Schade RR, Dugas MC, Lhotsky DM, Gavaler JS, van Thiel DH. Effect of metoclopramide on gastric liquid emptying in patients with diabetic gastroparesis. Dig Dis Sci 1985;30:10 15. Trapnell BC, Mavko LE, Birskovich LM, Falko JM. Metoclopramide suppositories in the treatment of diabetic gastroparesis. Arch Intern Med 1986;146:2278 2279. Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993;153: 1469 1475. Miller LG, Jankovic J. Metoclopramide-induced movement disorders. Clinical ndings with a review of the literature. Arch Intern Med 1989;149:2486 2492. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993;105:1886 1899. Feighner SD, Tan CP, McKee KK, Palyha OC, Hreniuk DL, Pong SS, Austin CP, Figueroa D, MacNeil D, Cascieri MA, Nargund R, Bakshi R, Abramovitz M, Stocco R, Kargman S, ONeill G, Van Der Ploeg LH, Evans J, Patchett AA, Smith RG, Howard AD. Receptor for motilin identied in the human gastrointestinal system. Science 1999;284:2184 2188. Parkman HP, Pagano AP, Vozzelli M, Ryan JP. Gastrokinetic effects of erythromycin: Myogenic and neurogenic mechanisms of action in the rabbit stomach. Am J Physiol 1995;269:G418 G426. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R. Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990; 322:1028 1031. Dull JS, Raufman J-P, Zakai MD, Strashun A, Straus EW. Successful treatment of gastroparesis with erythromycin in a patient with progressive systemic sclerosis. Am J Med 1990;89: 528 530. Mozwecz H, Pavel D, Pitrak D, Orellana P, Schlesinger PK, Layden TJ. Erythromycin stearate as prokinetic agent in postvagotomy gastroparesis. Dig Dis Sci 1990;35:902905. Klutman NE, Eisenach JB. Erythromycin therapy for gastroparesis. South Med J 1992;85:524 527. Erbas T, Varoglu E, Erbas B, Tastakin G, Akalin S. Comparison of metoclopramide and erythromycin in the treatment of diabetic gastroparesis. Diabetes Care 1993;16:15111514. Richards RD, Davenport K, McCallum RW. The treatment of idiopathic and diabetic gastroparesis with acute intravenous and chronic oral erythromycin. Am J Gastroenterol 1993;88: 203207. Ramirez B, Eaker EY, Drane WE, Hocking MP, Sninsky CA. Erythromycin enhances gastric emptying in patients with gastroparesis after vagotomy and antrectomy. Dig Dis Sci 1994;39: 22952300.
203. Samson M, Jebbink RJA, Akkermans LMA, Bravenboer B, vanBerge-Henegouwen GP, Smout AJPM. Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type 1 diabetes, measured with an ambulatory manometric technique. Diabetes Care 1997;20:129 134. 204. Talley NJ, Verlinden M, Geenen DJ, Hogan RB, Riff D, McCallum RW, Mack RJ. Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomized, double blind, placebo-controlled trial. Gut 2001; 49:395 401. 205. Camilleri M. The current role of erythromycin in the clinical management of gastric emptying disorders. Am J Gastroenterol 1993;88:169 171. 206. Maganti K, Onyemere K, Jones MP. Oral erythromycin and symptomatic relief of gastroparesis: a systematic review. Am J Gastroenterol 2003;98:259 263. 207. Ehrenpreis ED, Zaitman D, Nellans H. Which form of erythromycin should be used to treat gastroparesis? A pharmacologic analysis. Aliment Pharmacol Ther 1998;12:373376. 208. DiBaise JK, Quigley EMM. Efcacy of prolonged administration of intravenous erythromycin in an ambulatory setting as treatment of severe gastroparesis. J Clin Gastroenterol 1999;28: 131134. 209. Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, Brinkodd H, Eaker E, Ohning G, Miner PB, Mathias JR, Fumagalli I, Stassen J, Mack RJ. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000;14:16531661. 210. Nagler J, Miskovitz P. Clinical evaluation of domperidone in the treatment of chronic postprandial idiopathic upper gastrointestinal distress. Am J Gastroenterol 1981;76:495 499. 211. Watts GF, Armitage M, Sinclair J, Hill JD. Treatment of diabetic gastroparesis with oral domperidone. Diabetic Med 1985;2: 491 492. 212. Horowitz M, Harding PE, Chatterton BE, Collins PJ, Shearman DJC. Acute and chronic effects of domperidone on gastric emptying in diabetic autonomic neuropathy. Dig Dis Sci 1985;30: 19. 213. Champion MC, Gulenchyn K, OLeary T, Irvine P, Edwards A. Domperidone (motilium) improves symptoms and solid phase gastric emptying in diabetic gastroparesis. Am J Gastroenterol 1987;82:975980. 214. Davis RH, Clench MH, Mathias JR. Effects of domperidone in patients with chronic unexplained upper gastrointestinal symptoms. Dig Dis Sci 1988;33:15051511. 215. Soykan I, Sarosiek I, McCallum RW. The effect of chronic oral domperidone therapy on gastrointestinal symptoms, gastric emptying, and quality of life in patients with gastroparesis. Am J Gastroenterol 1997;92:976 980. 216. Silvers D, Kipnes M, Broadstone V, Patterson D, Quigley EMM, RcCallum R, Leidy NK, Farup C,Liu Y, Joslyn A. Domperidone in the management of symptoms of diabetic gastroparesis: efcacy, tolerability, and quality-of-live outcomes in a multicenter controlled trial. Clin Ther 1998;20:438 453. 217. Patterson D, Abell T, Rothstein R, Koch K, Barnett J. A doubleblind multicenter comparison of domperidone and metoclopramide in the treatment of diabetic patients with symptoms of gastroparesis. Am J Gastroenterol 1999;94:1230 1234. 218. Dumitrascu DL, Weinbeck M. Domperidone versus metoclopramide in the treatment of diabetic gastroparesis. Am J Gastroenterol 2000;95:316 317. 219. Jones MP. Access options for withdrawn motility-modifying agents. Am J Gastroenterol 2002;97:2184 2188. 220. Di Stefano M, Vos R, Janssens J, Tack JF. Effect of tegaserod, a 5-HT4 receptor partial agonist, on interdigestive and postpran-
November 2004
1621
221.
222.
223.
224.
225. 226.
227.
228.
229. 230.
231.
232.
233.
234.
235.
236.
237.
238.
239.
dial gastrointestinal motility in healthy volunteers (abstr). Gastroenterology 2003;124:A163. Degen L, Matzinger D, Merz M, Appel-Dingemanse S, Osborne S, Luchinger S, Bertold R, Maecke H, Beglinger C. Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects. Aliment Pharmacol Ther 2001;15:17451751. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000;118:463 468. Tougas G, Chen Y, Luo D, Salter J, DElia T, Earnest DL. Tegaserod improves gastric emptying in patients with gastroparesis and dyspeptic symptoms (abstr). Gastroenterology 2003;124: A54 468. Tack J, Delia T, Ligozio G, Sue S, Lefkowitz M, Vandeplassche L. A phase II trial with tegaserod in functional dyspepsia patients with normal gastric emptying (abstr). Gastroenterology 2002; 120:A20 468. Rabine JC, Barnett JL. Management of the patient with gastroparesis. J Clin Gastroenterol 2001;32:1118. Kishibayashi N, Karasawa A. Effects of KW-5092 on antroduodenal coordination and gastric emptying in guinea pigs. J Pharm Pharmacol 1998;50:10451050. Braida D, Virag W, Ottonello F, Sala M. Excitatory and inhibitory effects of second-generation cholinesterase inhibitors on rat gastrointestinal transit. Pharmacol Res 2000;41:671 677. Tatsuta M, Iishi H, Nakaizumi A, Okuda S. Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. Aliment Pharm Ther 1992;6:221228. Clouse RE. Antidepressants for functional gastrointestinal syndromes. Dig Dis Sci 1994;39:23522363. Prakash C, Lustman PJ, Freedland KE, Clouse RE. Tricyclic antidepressants for functional nausea and vomiting: clinical outcome in 37 patients. Dig Dis Sci 1998;43:19511956. Loldrup D, Langemark M, Hansen HJ, Olesen J, Beck P. Clomipramine and mianserin in chronic idiopathic pain syndrome: a placebo controlled study. Psychopharmacology 1989;99:17. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998;93:160 165. Sawhney MS, Prakash C, Lustman PJ, Clouse RE. Tricyclic antidepressants for persistent or recurrent vomiting in diabetic patients (abstr). Gastroenterology 2001;120:A243. Abouezzi ZE, Melvin WS, Ellison EC, Schirmer WJ. Functional and symptomatic improvement in patients with diabetic gastroparesis following pyloroplasty (abstr). Gastroenterology 1998; 114:A1374. Pasricha PJ, Ravich WJ, Hendrix TR, Sostre S, Jones B, Kallo AN. Intrasphincteric botulinum toxin for the treatment of achalasia. N Engl J Med 1995;332:775778. Sharma VK, Glassman SB, Howden CW, Vasudeva R. Pyloric intrasphincteric botulinum toxin (Botox) improved symptoms and gastric emptying in a patient with diabetic gastroparesis (abstr). Am J Gastroenterol 1998;93:456. Lacy BE, Schettler-Duncan VA, Crowell MD. The treatment of diabetic gastroparesis with botulinum toxin (abstr). Am J Gastroenterol 2000;95:24552456. Muddasani P, Ismail-Beigi F. Diabetic gastroparesis a possible new indication for botulinum toxin ingection (abstr). Am J Gastroenterol 2001;97:S255. Ezzeddine D, Jit R, Katz N, Gopalswamy N, Bhutani MS. Pyloric injection of botulinum toxin for treatment of diabetic gastroparesis. Gastrointest Endosc 2002;55:920 923.
240. Lacy BE, Zayat EN, Crowell MD, Schuster MM. Botulinum toxin for the treatment of gastroparesis: a preliminary report. Am J Gastroenterol 2002;97:1548 1552. 241. Miller LS, Szych GA, Kantor SB, Bromer MQ, Knight LC, Maurer AH, Fisher RS, Parkman HP. Treatment of idiopathic gastroparesis with injection of botulinum toxin into the pyloric sphincter muscle. Am J Gastroenterol 2002;97:16531660. 242. Arts J, Van Gool S, Caenepeel P, Janssens J, Tack. Effect of intrapyloric injection of Botulinum toxin on gastric emptying and meal-related symptoms in gastroparesis (abstr). Gastroenterology 2003;124:A53. 243. Familoni BO, Abell TL, Voeller G, Samem A, Gaber O. Electrical stimulation at a frequency higher than basal rate in human stomach. Dig Dis Sci 1997;42:885 891. 244. McCallum RW, Chen JDZ, Lin Z, Schirmer BD, Williams RD, Ross RA. Gastric pacing improves emptying and symptoms in patients with gastroparesis. Gastroenterology 1998;114: 456 461. 245. Forster J, Sarosiek I, Delcore R, Lin Z, Raju GS, McCallum RW. Gastric pacing is a new surgical treatment for gastroparesis. Am J Surg 2001;182:676 681. 246. Sobrino MA, Patterson DJ, Thirlby RC. Health-related quality of life with gastric electrical stimulation for gastroparesis (abstr). Am J Gastroenterol 2002;97:S57. 247. Skole KS, Panganamamula KV, Bromer MQ, Thomas P, Meilahn JE, Fisher RS, Parkman HP. Efcacy of gastric electrical stimulation for gastroparesis refractory to medical therapy: a single center experience (abstr). Am J Gastroenterol 2002;97:S48. 248. Abell TL, Van Cutsem E, Abrahamsson H, Huizinga JD, Konturek JW, Galmiche JP, Voeller G, Filez L, Everts B, Waterfall WE, Domschke W, Bruley des Varannes S, Familoni BO, Bourgeois IM, Janssens J, Tougas G. Gastric electrical stimulation in intractable symptomatic gastroparesis. Digestion 2002; 66:204 212. 249. Abell T, McCallum R, Hocking M, Koch K, Abrahamsson H, LeBlanc I, Lindberg G, Konturek J, Nowak T, Quigley EMM, Tougas G, Starkebaum W. Gastric electrical stimulation for medically refractory gastroparesis. Gastroenterology 2003; 125:421 428. 250. Abell T, Lou J, Tabbaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electric stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term followup. J Parenter Enteral Nutr 2003;27:277281. 251. Jones MP, Ebert CC, Murayama K. Enterra for gastroparesis (letter). Am J Gastroenterol 2003;98:2578. 252. Mintchev MP, Sanmiguel CP, Amaris M, Bowes KL. Microprocessor-controlled movement of solid gastric content using sequential neural electrical stimulation. Gastroenterology 2000; 118:258 263. 253. Jones MP, Maganti K. A systematic review of surgical therapy for gastroparesis. Am J Gastroenterol 2003;98:21222129. 254. Kim CH, Nelson DK. Venting percutaneous gastrostomy in the treatment of refractory idiopathic gastroparesis. Gastrointest Endosc 1998;47:6770. 255. Fontana RJ, Barnett JL. Jejunostomy tube placement in refractory diabetic gastroparesis: a retrospective review. Am J Gastroenterol 1996;91:2174 2178. 256. Jacober SJ, Narayan A, Stroedel WE, Vinik AI. Jejunostomy feeding in the management of gastroparesis diabeticorum. Diabetes Care 1986;9:217219. 257. Hotokezaka M, Adams RB, Miller AD, McCallum RW, Schirmer BD. Laparoscopic percutaneous jejunostomy for long term enteral access. Surg Endosc 1996;10:1008 1011. 258. Watkins PJ, Buxton-Thomas MS, Howard ER. Long-term outcome after gastrectomy for intractable diabetic gastroparesis. Diabetic Med 2003;20:58 63.
1622
259. Karlstrom L, Kelly KA. Roux-Y gastrectomy for chronic gastric atony. Am J Surg 1989;157:44 49. 260. McCallum RW, Polepalle SC, Schirmer B. Completion gastrectomy for refractory gastroparesis following surgery for peptic ulcer disease. Dig Dis Sci 1991;36:1556 1561. 261. Eckhauser RE, Conrad M, Knol JA, Mulholland MW, Colletti LM. Safety and long-term durability of completion gastrectomy in 81 patients with postsurgical gastroparesis syndrome. Am Surg 1998;64:711717. 262. Forstner-Barthell AW, Murr MM, Nitecki S, Camilleri M, Pranther CM, Kelly KA, Sarr MG. Near-total completion gastrectomy for severe postvagotomy gastric stasis. J Gastrointest Surg 1999; 3:1521. 263. Murat A, Pouliquen B, Cantarovich D, Lucas B, Bizais Y, Vecchierini MF, Charbonnel B, Galmiche JP, Soulillou JP. Gastric emptying improvement after simultaneous segmental pancreas and kidney transplantation. Transplant Proc 1992;24:855. 264. Kennedy WR, Navarro X, Goetz RC, Sutherland DER, Najarian JS. Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990;322:10317. 265. Hathaway DK, Abell T, Cardoso S, Hartwig MS, El Gebely S, Gaber AO. Improvement in autonomic and gastric function following pancreas-kidney versus kidney-alone transplantation and the correlation with quality of life. Transplantation 1994;57: 816 822. 266. Mansi C, Borro P, Giacomini M, Biagini R, Mele MR, Pandolfo N, Savarino V. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000; 14:561569. 267. Schwizer W, Borovicka J, Kunz P, Fraser R, Kreiss C, DAmato M, Crelier G, Boesiger P, Fried M. Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide. Gut 1997; 41:500 504. 268. Tack J, Coulie B, Andrioli A, Janssens J. Inuence of sumatriptan on gastric fundus tone and of the perception of gastric distension in man. Gut 2000;46:468 473. 269. Thumshirn M, Camilleri M, Cho M-G, Zinsmeister AR. Modulation of gastric sensory and motor functions by nitrergic and alpha-2 adrenergic agents. Gastroenterology 1999;116:573 585. 270. Rosa-E-Silva L, Troncon LES, Oliveira RB, Iazigi N, Gallo L, Foss MC. Treatment of diabetic gastroparesis with oral clonidine. Aliment Pharmacol Ther 1995;9:179 183. 271. Gullikson GW, Virina MA, Loefer R, Erwin WD. Alpha-2-adrenergic model of gastroparesis. Am J Physiol 1991;261:G426 G432. 272. Sarnelli G, Vos R, Sifrim D, Janssens J, Tack J. Inuence of sildenal on fasting and postprandial gastric tone in man (abstr). Gastroenterology 2001;120:A285A286. 273. de Rosalmeida MC, Saraiva LD, da Graca JR, Ivo BB, da Nobrega MV, Gondim FA, Rola FH, dos Santos AA. Sildenal, a
274.
275.
276.
277.
278.
279.
280.
281.
282.
283.
284.
285.
phosphodiesterase-5 inhibitor, delays gastric emptying and gastrointestinal transit of liquid in awake rats. Dig Dis Sci 2003;48:2064 2068. Rothstein RD, Alavi A, Reynolds JC. Electrogastrography in patients with gastroparesis and effect of long-term cisapride. Dig Dis Sci 1993;38:1518 1524. Pimentel M, Sam C, Lin HC. Indomethacin improves symptoms and electrogastrographic ndings in patients with gastric dysrhythmias. Neurogastroenterol Motil 2001;13:422. Gonlachanvit S, Chen YH, Hasler WL, Sun WM, Owyang C. Ginger reduces hyperglycemia-evoked gastric dysrhythmias in healthy humans: possible role of endogenous prostaglandins. J Pharmacol Exp Ther 2003;307:1098 1103. Calvert EL, Hughton LA, Cooper P, Whorwell PJ. Hypnotherapy is effective in the long-term treatment of functional dyspepsia (abstr). Gastroenterology 2001;120:A115. Hamilton J, Guthrie E, Creed F, Thompson D, Tomenson B, Bennett R, Muriarty K, Liston R. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000;119:661 669. Rashed H, Cutts T, Abell T, Cowings P, Toscano W, El-Gammal A, Adl D. Predictors of response to a behavioral treatment in patients with chronic gastric motility disorders. Dig Dis Sci. 2002;47:1020 1026. Dundee JW, Ghaly RG, Bill KM, Chestnutt WN, Fitzpatrick KTJ, Lynas AGA. Effect of stimulation of the P6 antiemetic point on postoperative nausea and vomiting. Br J Anaesth 1989;63: 612 618. Shen J, Wenger N, Glaspy J, Hays RD, Albert PS, Choi C, Shekelle PG. Electroacupuncture for control of myeloablative chemotherapy-induced emesis. JAMA 2000;284:27552761. De Aloysio D, Penacchioni P. Morning sickness control in early pregnancy by Neiguan point acupressure. Obstet Gynecol 1992; 80:852 854. Ouyang H, Yin J, Wang Z, Pasricha PJ, Chen JDZ. Electroacupuncture accelerates gastric emptying in association with changes in vagal activity. Am J Physiol 2002;282:G390 G396. Lin X, Liang J, Ren J, Mu F, Zhang M, Chen JD. Electrical stimulation of acupuncture points enhances gastric myoelectrical activity in humans. Am J Gastroenterol 1997;92:1527 1530. NIH Consensus Development Panel on Acupuncture. Acupuncture. JAMA 1998;280:1518 1524.
Address requests for reprints to: Chair, Clinical Practice Committee, AGA National Ofce, c/o Membership Department, 4930 Del Ray Avenue, Bethesda, Maryland 20814. Fax: (301) 654-5920. The Clinical Practice Committee acknowledges the following individuals whose critiques of this review paper provided valuable guidance to the authors: Jeffrey A. Barnett, MD, Manoop S. Bhutani, MD, Jay Pascricha, MD, and John C. Rabine, MD.

Gastroparesis

Încărcat de

Informații document

Descriere originală:

Drepturi de autor

Formate disponibile

Partajați acest document

Partajați sau inserați document

Opțiuni de partajare

Vi se pare util acest document?

Este necorespunzător acest conținut?

Drepturi de autor:

Formate disponibile

Gastroparesis

Încărcat de

Drepturi de autor:

Formate disponibile

GASTROENTEROLOGY 2004;127:15921622

Symptoms and Clinical Presentation of Gastroparesis

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

Table 1. Evaluation of Patients Suspected to Have Gastroparesis

Evaluation of Patients With Suspected Gastroparesis

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

GASTROENTEROLOGY Vol. 127, No. 5

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

Table 2. Tests to Assess Gastric Motor and Myoelectrical Function

Breath tests using

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

GASTROENTEROLOGY Vol. 127, No. 5

Table 3. Medications That Affect Gastric Emptying

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

GASTROENTEROLOGY Vol. 127, No. 5

Table 4. Etiology of Gastroparesis (Nonobstructive Delayed Gastric Emptying)

Disorders With Delayed Gastric Emptying (Gastroparesis)

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

GASTROENTEROLOGY Vol. 127, No. 5

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

GASTROENTEROLOGY Vol. 127, No. 5

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

GASTROENTEROLOGY Vol. 127, No. 5

Treatment of Symptomatic Gastroparesis

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

GASTROENTEROLOGY Vol. 127, No. 5

Table 5. Prokinetic Agents for Gastroparesis

Muscarinic receptor agonist

FDA, Food and Drug Administration.

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

Table 6. Systematic Review of Studies on Oral Metoclopramide for Treatment of Gastroparesis

Snape et al, 1982182

McCallum et al, 1983183

Multicenter, placebo controlled Open label

Loo et al, 1984184

Ricci et al, 1985185

Erbas et al, 1993186

Randomized, single-blind, crossover Randomized, double-blind, multicenter

Patterson et al, 1999187

QID, 4 times a day; TID, 3 times a day.

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

GASTROENTEROLOGY Vol. 127, No. 5

Postvagotomy gastroparesis Idiopathic gastroparesis

Single-blind, randomized, crossover Open label

Richards et al, 1993201

Ramirez et al, 1994202

Samson et al, 1997203

Talley et al, 2001204

TID, 3 times a day; QID, 4 times a day.

AMERICAN GASTROENTEROLOGICAL ASSOCIATION

Table 8. Systematic Review of Studies on Oral Domperidone for Treatment of Gastroparesis

Diabetic gastroparesis Diabetic gastropathy

Champion et al, 1987213

Davis et al, 1988214

Koch et al, 19898

Soykan et al, 1997215 Open label

Dumitrascu and Weinbeck, 2000218

QID, 4 times a day; TID, 3 times a day.